Podcasts about new england journal

  • 1,337PODCASTS
  • 2,344EPISODES
  • 34mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • May 29, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about new england journal

Show all podcasts related to new england journal

Latest podcast episodes about new england journal

Conspirituality
259: MAHA is Project 2025's Trojan Horse

Conspirituality

Play Episode Listen Later May 29, 2025 67:00


We've been talking about RFK Jr for years, and even dedicated an entire chapter to him in our 2023 book—and we're going to keep covering him. Since his power and influence has only grown, and since he's now in charge of America's entire health apparatus, there's no way to avoid it. This week we catch up on the last few months of MAHA. Derek looks into why he believes Kennedy's apparatus, despite claims of being about health, is really a cover for Project 2025's deregulatory agenda. Julian discusses a recent paper published in the New England Journal of Medicine by Covid contrarians Marty Makary and Vinay Prasad, who now both work under Kennedy. Finally, Matthew will contemplate Kennedy's crude remarks on autism through the lens of disability politics. Show Notes What Has All This Restaurant Food Done to My Gut? Function Health is Another Theranosesque Scam MAHA's Goal Is Not Health: Robert Kennedy's movement promises more privatization RFK Jr. meets with health tech startups, most backed by Andreessen Horowitz COVID infection no longer gives lasting immunity Hybrid Immunity May Be the Key to Developing Better Vaccines Makary, Bhattacharya in New England Journal of Medicine Consequences of Work Requirements in Arkansas: Two-Year Impacts on Coverage, Employment, and Affordability of Care  Concerns About ABA-Based Intervention: An Evaluation and Recommendations - PMC  Adler-Bolton, Beatrice, and Artie Vierkant. 2022. Health Communism: A Surplus Manifesto. Verso Books. SURPLUS. Adler-Bolton, The New Inquiry. October 18, 2022.  Extractive Abandonment - Stimpunks Foundation  Social and medical models of disability and mental health: evolution and renewal - PMC Learn more about your ad choices. Visit megaphone.fm/adchoices

Your Diet Sucks
What the Science Really Says About Diet and Longevity

Your Diet Sucks

Play Episode Listen Later May 28, 2025 66:13


Join our Patreon and get access to monthly bonus episodes and more nutriton content!Can fasting really slow aging? Does calorie restriction work for humans, or just for mice and yeast? And how much protein do you actually need to age well? This week on Your Diet Sucks, we break down the evidence behind the most talked-about interventions in the longevity space, what holds up under scrutiny, what doesn't, and why you might not need a supplement stack to live longer, and enjoy life. We dig into:The actual science on calorie restriction, fasting, and supplements—and where the evidence stopsWhat inflammation, oxidative stress, and telomeres have to do with how we ageThe best-researched dietary patterns for living longer (hint: it's not sexy, but it might include red wine)Why protein becomes more important as we ageThe difference between lifespan and healthspan, and why quality of life needs to be part of the conversation

Behind The Knife: The Surgery Podcast
Journal Review and Clinical Challenges in Surgical Palliative Care: Assessing Decision-Making Capacity

Behind The Knife: The Surgery Podcast

Play Episode Listen Later May 22, 2025 25:42


Join the University of Washington Surgical Palliative Care Team for their final episode of this series — a dual journal review and clinical challenges discussion on assessing medical decision-making capacity. Using Dr. Paul Applebaum's foundational framework, the team outlines the four key criteria for evaluating capacity and brings the topic to life through two contrasting standardized patient scenarios. This episode highlights why capacity assessment is not only relevant but essential for surgeons navigating complex, high-stakes decisions.  Hosts:  Dr. Katie O'Connell (@katmo15) is an associate professor of surgery at the University of Washington. She is a trauma surgeon, palliative care physician, director of surgical palliative care, and founder of the Advance Care Planning for Surgery clinic at Harborview Medical Center, Seattle, WA. Dr. Ali Haruta is an assistant professor of surgery at the University of Washington. She is a trauma and emergency general surgeon and palliative care physician. Ali recently completed fellowships in palliative care at the University of Washington and Trauma and Critical Care at Parkland.  Dr. Lindsay Dickerson (@lindsdickerson1) is a PGY6 general surgery resident at the University of Washington with an interest in surgical oncology.   Dr. Virginia Wang is a PGY3 general surgery resident at the University of Washington. Learning Objectives: 1.        Decipher the distinction between the terms “capacity” and “competence”.   2.        Describe the four criteria for assessing medical decision-making capacity presented in Dr. Paul Applebaum's article “Assessment of Patients' Competence to Consent to Treatment.” 3.        Apply the capacity assessment framework to real-world clinical scenarios in surgical practice.  References: 1.        Applebaum, PS. Assessment of Patients' Competence to Consent to Treatment. New England Journal of Medicine 2007; 357(18):1834-1840. https://pubmed.ncbi.nlm.nih.gov/17978292/ 2.        Special thank you to Mr. Mark Fox for his acting contribution to this episode. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Kan English
Can joint Israeli-Palestinian health initiatives be bridge for trust?

Kan English

Play Episode Listen Later May 21, 2025 9:34


Can joint Israeli-Palestinian health programs help build trust where politics have failed? According to a new paper published in the New England Journal of Medicine, the health care field can play a crucial role in building bridges between communities in conflict. Written by two Jewish Israeli and two Palestinian doctors during a period of temporary ceasefire between Israel and Hamas, the paper reviews 16 joint initiatives, highlighting in particular two programs: Road to Recovery and Physicians for Human Rights Israel. The authors also present recommendations on how cross-national health care programs can play a role in post-war peacebuilding. One of the paper's authors, Avner Halperin, a senior fellow at the Harvard Kennedy School's Middle East Initiative, spoke to KAN reporter Naomi Segal. (Photo: Billie Weiss)See omnystudio.com/listener for privacy information.

HPE Tech Talk
What is an AI agent?

HPE Tech Talk

Play Episode Listen Later May 15, 2025 21:23


How do we make artificial intelligence more intelligent? This week, Technology Now dives deep into the world of AI agents and how they interact with large language models. We ask what are some of the current problems with AI, and examine how applying agents can help artificial intelligence to provide better answers to our questions. Jimmy Whitaker, Chief Scientist in the AI Private Cloud Group at HPE, tells us more.This is Technology Now, a weekly show from Hewlett Packard Enterprise. Every week, hosts Michael Bird and Aubrey Lovell look at a story that's been making headlines, take a look at the technology behind it, and explain why it matters to organizations and what can be learnt from it.Jimmy Whitaker: https://www.linkedin.com/in/jimmymwhitaker/Sources cited in this week's episode:Today I learned: https://www.simonsfoundation.org/2025/04/29/flares-from-magnetized-stars-can-forge-planets-worth-of-gold-other-heavy-elements/Anirudh Patel et al., 2025, Direct Evidence for r-process Nucleosynthesis in Delayed MeV Emission from the SGR 1806–20 Magnetar Giant Flare, ApJL 984 L29, DOI 10.3847/2041-8213/adc9b0This week in history:Strassburg MA. The global eradication of smallpox. Am J Infect Control. 1982 May;10(2):53-9. doi: 10.1016/0196-6553(82)90003-7. PMID: 7044193.Muyembe JJ, et al, 2024, Ebola Outbreak Response in the DRC with r-VSV-ZEBOV-GP Ring Vaccination, The New England Journal of Medicine, 2024;391:2327-2336, VOL. 391 NO.24, https://www.nejm.org/doi/10.1056/NEJMoa1904387https://www.who.int/health-topics/poliomyelitis#tab=tab_1

Cancer Stories: The Art of Oncology
An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last: Lessons on How NOT to Induce Coma in Your Audience

Cancer Stories: The Art of Oncology

Play Episode Listen Later May 13, 2025 27:23


Listen to ASCO's JCO Oncology Practice, Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last” by Dr. David Johnson, who is a clinical oncologist at University of Texas Southwestern Medical School. The article is followed by an interview with Johnson and host Dr. Mikkael Sekeres. Through humor and irony, Johnson critiques how overspecialization and poor presentation practices have eroded what was once internal medicine's premier educational forum. Transcript Narrator: An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last, by David H. Johnson, MD, MACP, FASCO   Over the past five decades, I have attended hundreds of medical conferences—some insightful and illuminating, others tedious and forgettable. Among these countless gatherings, Medical Grand Rounds (MGRs) has always held a special place. Originally conceived as a forum for discussing complex clinical cases, emerging research, and best practices in patient care, MGRs served as a unifying platform for clinicians across all specialties, along with medical students, residents, and other health care professionals. Expert speakers—whether esteemed faculty or distinguished guests—would discuss challenging cases, using them as a springboard to explore the latest advances in diagnosis and treatment. During my early years as a medical student, resident, and junior faculty member, Grand Rounds consistently attracted large, engaged audiences. However, as medicine became increasingly subspecialized, attendance began to wane. Lectures grew more technically intricate, often straying from broad clinical relevance. The patient-centered discussions that once brought together diverse medical professionals gradually gave way to hyperspecialized presentations. Subspecialists, once eager to share their insights with the wider medical community, increasingly withdrew to their own specialty-specific conferences, further fragmenting the exchange of knowledge across disciplines. As a former Chair of Internal Medicine and a veteran of numerous MGRs, I observed firsthand how these sessions shifted from dynamic educational exchanges to highly specialized, often impenetrable discussions. One of the most striking trends in recent years has been the decline in presentation quality at MGR—even among local and visiting world-renowned experts. While these speakers are often brilliant clinicians and investigators, they can also be remarkably poor lecturers, delivering some of the most uninspiring talks I have encountered. Their presentations are so consistently lackluster that one might suspect an underlying strategy at play—an unspoken method to ensure that they are never invited back. Having observed this pattern repeatedly, I am convinced that these speakers must be adhering to a set of unwritten rules to avoid future MGR presentations. To assist those unfamiliar with this apparent strategy, I have distilled the key principles that, when followed correctly, all but guarantee that a presenter will not be asked to give another MGR lecture—thus sparing them the burden of preparing one in the future. Drawing on my experience as an oncologist, I illustrate these principles using an oncology-based example although I suspect similar rules apply across other subspecialties. It will be up to my colleagues in cardiology, endocrinology, rheumatology, and beyond to identify and document their own versions—tasks for which I claim no expertise. What follows are the seven “Rules for Presenting a Bad Medical Oncology Medical Grand Rounds.” 1.  Microscopic Mayhem: Always begin with an excruciatingly detailed breakdown of the tumor's histology and molecular markers, emphasizing how these have evolved over the years (eg, PAP v prostate-specific antigen)—except, of course, when they have not (eg, estrogen receptor, progesterone receptor, etc). These nuances, while of limited relevance to general internists or most subspecialists (aside from oncologists), are guaranteed to induce eye-glazing boredom and quiet despair among your audience. 2. TNM Torture: Next, cover every nuance of the newest staging system … this is always a real crowd pleaser. For illustrative purposes, show a TNM chart in the smallest possible font. It is particularly helpful if you provide a lengthy review of previous versions of the staging system and painstakingly cover each and every change in the system. Importantly, this activity will allow you to disavow the relevance of all previous literature studies to which you will subsequently refer during the course of your presentation … to wit—“these data are based on the OLD staging system and therefore may not pertain …” This phrase is pure gold—use it often if you can. NB: You will know you have “captured” your audience if you observe audience members “shifting in their seats” … it occurs almost every time … but if you have failed to “move” the audience … by all means, continue reading … there is more! 3. Mechanism of Action Meltdown: Discuss in detail every drug ever used to treat the cancer under discussion; this works best if you also give a detailed description of each drug's mechanism of action (MOA). General internists and subspecialists just LOVE hearing a detailed discussion of the drug's MOA … especially if it is not at all relevant to the objectives of your talk. At this point, if you observe a wave of slack-jawed faces slowly slumping toward their desktops, you will know you are on your way to successfully crushing your audience's collective spirit. Keep going—you are almost there. 4. Dosage Deadlock: One must discuss “dose response” … there is absolutely nothing like a dose response presentation to a group of internists to induce cries of anguish. A wonderful example of how one might weave this into a lecture to generalists or a mixed audience of subspecialists is to discuss details that ONLY an oncologist would care about—such as the need to dose escalate imatinib in GIST patients with exon 9 mutations as compared with those with exon 11 mutations. This is a definite winner! 5. Criteria Catatonia: Do not forget to discuss the newest computed tomography or positron emission tomography criteria for determining response … especially if you plan to discuss an obscure malignancy that even oncologists rarely encounter (eg, esthesioneuroblastoma). Should you plan to discuss a common disease you can ensure ennui only if you will spend extra time discussing RECIST criteria. Now if you do this well, some audience members may begin fashioning their breakfast burritos into projectiles—each one aimed squarely at YOU. Be brave … soldier on! 6. Kaplan-Meier Killer: Make sure to discuss the arcane details of multiple negative phase II and III trials pertaining to the cancer under discussion. It is best to show several inconsequential and hard-to-read Kaplan-Meier plots. To make sure that you do a bad job, divide this portion of your presentation into two sections … one focused on adjuvant treatment; the second part should consist of a long boring soliloquy on the management of metastatic disease. Provide detailed information of little interest even to the most ardent fan of the disease you are discussing. This alone will almost certainly ensure that you will never, ever be asked to give Medicine Grand Rounds again. 7. Lymph Node Lobotomy: For the coup de grâce, be sure to include an exhaustive discussion of the latest surgical techniques, down to the precise number of lymph nodes required for an “adequate dissection.” To be fair, such details can be invaluable in specialized settings like a tumor board, where they send subspecialists into rapturous delight. But in the context of MGR—where the audience spans multiple disciplines—it will almost certainly induce a stultifying torpor. If dullness were an art, this would be its masterpiece—capable of lulling even the most caffeinated minds into a stupor. If you have carefully followed the above set of rules, at this point, some members of the audience should be banging their heads against the nearest hard surface. If you then hear a loud THUD … and you're still standing … you will know you have succeeded in giving the world's worst Medical Grand Rounds!   Final Thoughts I hope that these rules shed light on what makes for a truly dreadful oncology MGR presentation—which, by inverse reasoning, might just serve as a blueprint for an excellent one. At its best, an outstanding lecture defies expectations. One of the most memorable MGRs I have attended, for instance, was on prostaglandin function—not a subject typically associated with edge-of-your-seat suspense. Given by a biochemist and physician from another subspecialty, it could have easily devolved into a labyrinth of enzymatic pathways and chemical structures. Instead, the speaker took a different approach: rather than focusing on biochemical minutiae, he illustrated how prostaglandins influence nearly every major physiologic system—modulating inflammation, regulating cardiovascular function, protecting the gut, aiding reproduction, supporting renal function, and even influencing the nervous system—without a single slide depicting the prostaglandin structure. The result? A room full of clinicians—not biochemists—walked away with a far richer understanding of how prostaglandins affect their daily practice. What is even more remarkable is that the talk's clarity did not just inform—it sparked new collaborations that shaped years of NIH-funded research. Now that was an MGR masterpiece. At its core, effective scientific communication boils down to three deceptively simple principles: understanding your audience, focusing on relevance, and making complex information accessible.2 The best MGRs do not drown the audience in details, but rather illuminate why those details matter. A great lecture is not about showing how much you know, but about ensuring your audience leaves knowing something they didn't before. For those who prefer the structured wisdom of a written guide over the ramblings of a curmudgeon, an excellent review of these principles—complete with a handy checklist—is available.2 But fair warning: if you follow these principles, you may find yourself invited back to present another stellar MGRs. Perish the thought! Dr. Mikkael SekeresHello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the oncology field. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami.  What a pleasure it is today to be joined by Dr. David Johnson, clinical oncologist at the University of Texas Southwestern Medical School. In this episode, we will be discussing his Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Our guest's disclosures will be linked in the transcript.  David, welcome to our podcast and thanks so much for joining us. Dr. David JohnsonGreat to be here, Mikkael. Thanks for inviting me. Dr. Mikkael SekeresI was wondering if we could start with just- give us a sense about you. Can you tell us about yourself? Where are you from? And walk us through your career. Dr. David JohnsonSure. I grew up in a small rural community in Northwest Georgia about 30 miles south of Chattanooga, Tennessee, in the Appalachian Mountains. I met my wife in kindergarten. Dr. Mikkael SekeresOh my. Dr. David JohnsonThere are laws in Georgia. We didn't get married till the third grade. But we dated in high school and got married after college. And so we've literally been with one another my entire life, our entire lives. Dr. Mikkael SekeresMy word. Dr. David JohnsonI went to medical school in Georgia. I did my training in multiple sites, including my oncology training at Vanderbilt, where I completed my training. I spent the next 30 years there, where I had a wonderful career. Got an opportunity to be a Division Chief and a Deputy Director of, and the founder of, a cancer center there. And in 2010, I was recruited to UT Southwestern as the Chairman of Medicine. Not a position I had particularly aspired to, but I was interested in taking on that challenge, and it proved to be quite a challenge for me. I had to relearn internal medicine, and really all the subspecialties of medicine really became quite challenging to me. So my career has spanned sort of the entire spectrum, I suppose, as a clinical investigator, as an administrator, and now as a near end-of-my-career guy who writes ridiculous articles about grand rounds. Dr. Mikkael SekeresNot ridiculous at all. It was terrific. What was that like, having to retool? And this is a theme you cover a little bit in your essay, also, from something that's super specialized. I mean, you have had this storied career with the focus on lung cancer, and then having to expand not only to all of hematology oncology, but all of medicine. Dr. David JohnsonIt was a challenge, but it was also incredibly fun. My first few days in the chair's office, I met with a number of individuals, but perhaps the most important individuals I met with were the incoming chief residents who were, and are, brilliant men and women. And we made a pact. I promised to teach them as much as I could about oncology if they would teach me as much as they could about internal medicine. And so I spent that first year literally trying to relearn medicine. And I had great teachers. Several of those chiefs are now on the faculty here or elsewhere. And that continued on for the next several years. Every group of chief residents imparted their wisdom to me, and I gave them what little bit I could provide back to them in the oncology world. It was a lot of fun. And I have to say, I don't necessarily recommend everybody go into administration. It's not necessarily the most fun thing in the world to do. But the opportunity to deal one-on-one closely with really brilliant men and women like the chief residents was probably the highlight of my time as Chair of Medicine. Dr. Mikkael SekeresThat sounds incredible. I can imagine, just reflecting over the two decades that I've been in hematology oncology and thinking about the changes in how we diagnose and care for people over that time period, I can only imagine what the changes had been in internal medicine since I was last immersed in that, which would be my residency. Dr. David JohnsonWell, I trained in the 70s in internal medicine, and what transpired in the 70s was kind of ‘monkey see, monkey do'. We didn't really have a lot of understanding of pathophysiology except at the most basic level. Things have changed enormously, as you well know, certainly in the field of oncology and hematology, but in all the other fields as well. And so I came in with what I thought was a pretty good foundation of knowledge, and I realized it was completely worthless, what I had learned as an intern and resident. And when I say I had to relearn medicine, I mean, I had to relearn medicine. It was like being an intern. Actually, it was like being a medical student all over again. Dr. Mikkael SekeresOh, wow. Dr. David JohnsonSo it's quite challenging.  Dr. Mikkael SekeresWell, and it's just so interesting. You're so deliberate in your writing and thinking through something like grand rounds. It's not a surprise, David, that you were also deliberate in how you were going to approach relearning medicine. So I wonder if we could pivot to talking about grand rounds, because part of being a Chair of Medicine, of course, is having Department of Medicine grand rounds. And whether those are in a cancer center or a department of medicine, it's an honor to be invited to give a grand rounds talk. How do you think grand rounds have changed over the past few decades? Can you give an example of what grand rounds looked like in the 1990s compared to what they look like now? Dr. David JohnsonWell, I should all go back to the 70s and and talk about grand rounds in the 70s. And I referenced an article in my essay written by Dr. Ingelfinger, who many people remember Dr. Ingelfinger as the Ingelfinger Rule, which the New England Journal used to apply. You couldn't publish in the New England Journal if you had published or publicly presented your data prior to its presentation in the New England Journal. Anyway, Dr. Ingelfinger wrote an article which, as I say, I referenced in my essay, about the graying of grand rounds, when he talked about what grand rounds used to be like. It was a very almost sacred event where patients were presented, and then experts in the field would discuss the case and impart to the audience their wisdom and knowledge garnered over years of caring for patients with that particular problem, might- a disease like AML, or lung cancer, or adrenal insufficiency, and talk about it not just from a pathophysiologic standpoint, but from a clinician standpoint. How do these patients present? What do you do? How do you go about diagnosing and what can you do to take care of those kinds of patients? It was very patient-centric. And often times the patient, him or herself, was presented at the grand rounds. And then experts sitting in the front row would often query the speaker and put him or her under a lot of stress to answer very specific questions about the case or about the disease itself.  Over time, that evolved, and some would say devolved, but evolved into more specialized and nuanced presentations, generally without a patient present, or maybe even not even referred to, but very specifically about the molecular biology of disease, which is marvelous and wonderful to talk about, but not necessarily in a grand round setting where you've got cardiologists sitting next to endocrinologists, seated next to nephrologists, seated next to primary care physicians and, you know, an MS1 and an MS2 and et cetera. So it was very evident to me that what I had witnessed in my early years in medicine had really become more and more subspecialized. As a result, grand rounds, which used to be packed and standing room only, became echo chambers. It was like a C-SPAN presentation, you know, where local representative got up and gave a talk and the chambers were completely empty. And so we had to go to do things like force people to attend grand rounds like a Soviet Union-style rally or something, you know. You have to pay them to go. But it was really that observation that got me to thinking about it.  And by the way, I love oncology and I'm, I think there's so much exciting progress that's being made that I want the presentations to be exciting to everybody, not just to the oncologist or the hematologist, for example. And what I was witnessing was kind of a formula that, almost like a pancake formula, that everybody followed the same rules. You know, “This disease is the third most common cancer and it presents in this way and that way.” And it was very, very formulaic. It wasn't energizing and exciting as it had been when we were discussing individual patients. So, you know, it just is what it is. I mean, progress is progress and you can't stop it. And I'm not trying to make America great again, you know, by going back to the 70s, but I do think sometimes we overthink what medical grand rounds ought to be as compared to a presentation at ASH or ASCO where you're talking to subspecialists who understand the nuances and you don't have to explain the abbreviations, you know, that type of thing. Dr. Mikkael SekeresSo I wonder, you talk about the echo chamber of the grand rounds nowadays, right? It's not as well attended. It used to be a packed event, and it used to be almost a who's who of, of who's in the department. You'd see some very famous people who would attend every grand rounds and some up-and-comers, and it was a chance for the chief residents to shine as well. How do you think COVID and the use of Zoom has changed the personality and energy of grand rounds? Is it better because, frankly, more people attend—they just attend virtually. Last time I attended, I mean, I attend our Department of Medicine grand rounds weekly, and I'll often see 150, 200 people on the Zoom. Or is it worse because the interaction's limited? Dr. David JohnsonYeah, I don't want to be one of those old curmudgeons that says, you know, the way it used to be is always better. But there's no question that the convenience of Zoom or similar media, virtual events, is remarkable. I do like being able to sit in my office where I am right now and watch a conference across campus that I don't have to walk 30 minutes to get to. I like that, although I need the exercise. But at the same time, I think one of the most important aspects of coming together is lost with virtual meetings, and that's the casual conversation that takes place. I mentioned in my essay an example of the grand rounds that I attended given by someone in a different specialty who was both a physician and a PhD in biochemistry, and he was talking about prostaglandin metabolism. And talk about a yawner of a title; you almost have to prop your eyelids open with toothpicks. But it turned out to be one of the most fascinating, engaging conversations I've ever encountered. And moreover, it completely opened my eyes to an area of research that I had not been exposed to at all. And it became immediately obvious to me that it was relevant to the area of my interest, which was lung cancer. This individual happened to be just studying colon cancer. He's not an oncologist, but he was studying colon cancer. But it was really interesting what he was talking about. And he made it very relevant to every subspecialist and generalist in the audience because he talked about how prostaglandin has made a difference in various aspects of human physiology.  The other grand rounds which always sticks in my mind was presented by a long standing program director at my former institution of Vanderbilt. He's passed away many years ago, but he gave a fascinating grand rounds where he presented the case of a homeless person. I can't remember the title of his grand rounds exactly, but I think it was “Care of the Homeless” or something like that. So again, not something that necessarily had people rushing to the audience. What he did is he presented this case as a mysterious case, you know, “what is it?” And he slowly built up the presentation of this individual who repeatedly came to the emergency department for various and sundry complaints. And to make a long story short, he presented a case that turned out to be lead poisoning. Everybody was on the edge of their seat trying to figure out what it was. And he was challenging members of the audience and senior members of the audience, including the Cair, and saying, “What do you think?” And it turned out that the patient became intoxicated not by eating paint chips or drinking lead infused liquids. He was burning car batteries to stay alive and inhaling lead fumes, which itself was fascinating, you know, so it was a fabulous grand rounds. And I mean, everybody learned something about the disease that they might otherwise have ignored, you know, if it'd been a title “Lead Poisoning”, I'm not sure a lot of people would have shown up. Dr. Mikkael Sekeres That story, David, reminds me of Tracy Kidder, who's a master of the nonfiction narrative, will choose a subject and kind of just go into great depth about it, and that subject could be a person. And he wrote a book called Rough Sleepers about Jim O'Connell - and Jim O'Connell was one of my attendings when I did my residency at Mass General - and about his life and what he learned about the homeless. And it's this same kind of engaging, “Wow, I never thought about that.” And it takes you in a different direction.  And you know, in your essay, you make a really interesting comment. You reflect that subspecialists, once eager to share their insight with the wider medical community, increasingly withdraw to their own specialty specific conferences, further fragmenting the exchange of knowledge across disciplines. How do you think this affects their ability to gain new insights into their research when they hear from a broader audience and get questions that they usually don't face, as opposed to being sucked into the groupthink of other subspecialists who are similarly isolated? Dr. David Johnson That's one of the reasons I chose to illustrate that prostaglandin presentation, because again, that was not something that I specifically knew much about. And as I said, I went to the grand rounds more out of a sense of obligation than a sense of engagement. Moreover, our Chair at that institution forced us to go, so I was there, not by choice, but I'm so glad I was, because like you say, I got insight into an area that I had not really thought about and that cross pollination and fertilization is really a critical aspect. I think that you can gain at a broad conference like Medical Grand Rounds as opposed to a niche conference where you're talking about APL. You know, everybody's an APL expert, but they never thought about diabetes and how that might impact on their research. So it's not like there's an ‘aha' moment at every Grand Rounds, but I do think that those kinds of broad based audiences can sometimes bring a different perspective that even the speaker, him or herself had not thought of. Dr. Mikkael SekeresI think that's a great place to end and to thank David Johnson, who's a clinical oncologist at the University of Texas Southwestern Medical School and just penned the essay in JCO Art of Oncology Practice entitled "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Until next time, thank you for listening to JCO's Cancer Stories: The Art of Oncology. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all of ASCO's shows at asco.org/podcasts.  David, once again, I want to thank you for joining me today. Dr. David JohnsonThank you very much for having me. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Show notes: Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr David Johnson is a clinical oncologist at the University of Texas Southwestern Medical School.

CBS This Morning - News on the Go
Nicole Scherzinger On How "Sunset Blvd." Changed Her Life | New Study Compares Effectiveness of Weight Loss Drugs

CBS This Morning - News on the Go

Play Episode Listen Later May 12, 2025 38:57


CBS News MoneyWatch correspondent Kelly O'Grady breaks down what to know about the potential financial impact to American consumers after the U.S. and China agreed to temporarily ease tariffs. Music superstar Taylor Swift has been subpoenaed in the ongoing legal dispute between Blake Lively and Justin Baldoni over allegations surrounding the making of their 2024 film "It Ends with Us."  A new study from the New England Journal of Medicine compares two weight loss drugs, Tirzepatide and Semaglutide. CBS News medical contributor Dr. Celine Gounder breaks down the findings. Nicole Scherzinger is making her Broadway debut in the stripped down, modern revival of "Sunset Blvd." She talks with "CBS Mornings" about the show, taking on the role and her first Tony nomination. In an exclusive "Begnaud's America" interview, CBS News contributor David Begnaud speaks with Gus Waltz, the son of Minnesota Gov. Tim Walz, who stole the spotlight during the 2024 Democratic National Convention. He's opening up about that moment and a learning disorder that is often misunderstood. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Redefining Medicine
Redefining Medicine with special guest Florence Comite, MD

Redefining Medicine

Play Episode Listen Later May 12, 2025 15:39


Dr. Florence Comite, MD is a clinician-scientist, endocrinologist, and the leading expert in the fields of healthy longevity and precision medicine. Her international reputation stems from her innovative approach to leveraging proprietary clinical and wearable data in her private clinical and virtual practice to detect, predict, and reverse biological aging, while optimizing health and vitality.   As a graduate of Yale School of Medicine, Dr. Comite served as a faculty member for twenty-five years with a distinguished triple appointment in Endocrinology (Internal Medicine and Pediatrics) and Reproductive Endocrinology (Gynecology and Andrology). During her career, she trained at the National Institutes of Health and founded Women's Health at Yale, establishing the nation's first women-only clinic.   In 2005, Dr. Comite founded the Comite Center for Precision Medicine & Healthy Longevity in New York City, where she developed the groundbreaking Nof1™ clinical process, treating each patient as a single subject clinical trial. The Center's success has led to expansions in Palo Alto and Miami Beach. Her innovative approach has attracted a global clientele, including forward-thinking physicians, industry leaders, and entrepreneurs, each receiving personalized healthcare interventions tailored to their individual needs. Her commitment to advancing medical science is evident through her extensive research and publications in prestigious journals such as the New England Journal of Medicine, JAMA: The Journal of the American Medical Association, and the Journal of the Endocrine Society. Dr. Comite's pioneering research spans across children, women, and men, recognizing the critical role of the entire system in aging and disease.   In 2013, she authored the bestselling book "Keep It Up: The Power of Precision Medicine to Conquer Low T and Revitalize Your Life," focusing on androgen deficiency and vitality in aging men. Her next book, "Invincible: Eliminate the Disorders of Aging for a Healthy, Long Life," will be published by Little Brown, Spark in Spring 2026. Through her startup Groq Health, Dr. Comite is scaling her precise methodology of precision medicine to a digital clinic delivered virtually.   As a sought-after keynote speaker, Dr. Comite continues to captivate audiences worldwide, sharing her expertise and vision for the future of precision medicine and healthy longevity.

Ask Dr. Drew
DOJ Investigating Medical Journals For Fraud; Publishers Call Letters “Harassment” w/ Elijah Schaffer & Dr. Ram Yogendra – Ask Dr. Drew – Ep 481

Ask Dr. Drew

Play Episode Listen Later May 9, 2025 78:16


The DOJ is investigating top medical journals for biased editorial practices, alleging they suppressed studies on COVID-19 vaccine risks and alternative therapeutics for partisan reasons. NBC reports the science publications (including CHEST, New England Journal of Medicine, and Obstetrics and Gynecology) were sent letters “questioning their editorial practices.” In response, medical journal The Lancet called the letters “harassment” and claimed science in the USA was being “violently dismembered” by all of these annoying questions being asked by the peasants. “This corrupt web of suppression, fraud, and retractions demands a legal reckoning,” writes epidemiologist Nicolas Hulscher. Dr. Ram Yogendra, MD, MHP, is a board-certified anesthesiologist with a public health background. He advocates for vaccine injury research, highlighting issues like the persistence of S1 spike protein in monocytes post-COVID-19 vaccination. More at https://x.com/dryostradamus and https://covidlonghaulers.com Elijah Schaffer is a journalist for The Gateway Pundit and the host of Slightly Offensive on Censored.TV. He's also a news presenter on Vigilant News Network. Schaffer filmed the Kyle Rittenhouse shootings, was inside the Capitol on January 6, 2021, and went undercover in groups like Antifa and BLM during the 2020 riots. More at https://x.com/ElijahSchaffer 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠https://drdrew.com/sponsors⁠⁠  ⁠⁠⁠ • FRESH PRESSED OLIVE OIL – Olive oil packs the most flavor and healthiest nutrients when it's fresh. Don't settle for stale supermarket olive oils – get it direct from small, award-winning farms! Get your free $39 bottle for just $1 shipping & taste the difference at ⁠https://GetFreshDrDrew.com/ • ACTIVE SKIN REPAIR - Repair skin faster with more of the molecule your body creates naturally! Hypochlorous (HOCl) is produced by white blood cells to support healing – and no sting. Get 20% off at ⁠⁠https://drdrew.com/skinrepair⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠https://drdrew.com/fatty15⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠https://drdrew.com/paleovalley⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠https://twc.health/drew⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠https://kalebnation.com⁠⁠) and Susan Pinsky (⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠e⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

EN POCAS PALABRAS
Lo que puede hacerse con Inteligencia Artificial

EN POCAS PALABRAS

Play Episode Listen Later May 7, 2025 4:12


Un nuevo estudio sobre inteligencia artificial publicado en The New England Journal of Medicine, indica cómo un chatbot de IA llamado Therabot puede mejorar significativamente los síntomas en solo dos meses para aquellos que sufren de trastorno depresivo mayor trastorno de ansiedad generalizada y trastornos alimentarios. El Therabot tiene el potencial de arreglar tratamientos de salud mental altamente personalizados y efectivos a gran escala, a la vez que abordan problemas de compromiso y retención de usuarios en los tratamientos.

The Busy Leader’s Podcast - A Catalyst for Inspired Action
114_How Mindset, Synergy, and Lifestyle Basics Help Healthcare Professionals Battle Burnout

The Busy Leader’s Podcast - A Catalyst for Inspired Action

Play Episode Listen Later May 5, 2025 43:47


In this episode of the Healthcare Plus Podcast, Quint Studer is joined by Dr. Roger Kapoor, physician leader and author of Working Happy!: How to Survive Burnout and Find Your Work/Life Synergy in the Healthcare Industry. Quint and Dr. Kapoor dive deep into one of healthcare's most urgent challenges: burnout. Drawing from personal experience, clinical insight, and extensive research, Dr. Kapoor explores why so many healthcare professionals are feeling overwhelmed—and what we can do about it. He explains that burnout isn't just a workplace issue; it often starts within ourselves, and recognizing this can be the first step toward healing.Listeners will hear why “work/life balance” may be a flawed concept and how “work/life synergy” can offer a more sustainable, fulfilling way forward. They'll learn about the powerful concept of ikigai (a Japanese term for “reason for being”) and how finding purpose in even the smallest moments can bring resilience and joy back to a healthcare career. Dr. Kapoor also explores fundamentals like diet, exercise, and sleep in a way that's fresh and compelling. (You'll love his insights on the “night shift janitors” that clear out the waste in our brains.)This episode is a must-listen for anyone in healthcare who's grappling with stress, seeking practical ways to recharge, or simply wanting to reconnect with the meaning behind their work.About Dr. Roger KapoorRoger Kapoor, MD, MBA, is the senior vice president of Beloit Health System in Beloit, Wisconsin, a community-based nonprofit hospital with approximately 23 service locations. He is a Harvard-trained dermatologist who also holds an MBA from the University of Oxford in England and has authored numerous peer-reviewed scientific articles published in professional journals including the New England Journal of Medicine. He was the recipient of the Wisconsin Medical Society's Kenneth M. Viste, Jr., MD, Young Physician Leadership Award and named one of the Top 25 Emerging Leaders in Healthcare by Modern Healthcare.  Kapoor has been credited with re-engineering the delivery of healthcare to his community, resulting in a dramatic rise in patient satisfaction at his institution from a stagnant 16th percentile to an astonishing 88th percentile in less than a year. He concurrently ushered in transformative results in quality, leading teams to achieve three consecutive “A” ratings from the national watchdog group Leapfrog, a four-star rating from the Centers for Medicare & Medicaid Services Five-Star Quality Rating System, and numerous quality-of-care pathway accolades. As a practicing board-certified dermatologist, he has built a successful medical and cosmetic dermatology practice using advanced techniques to help patients live happier, healthier lives. His book Working Happy! How to Survive Burnout and Find Your Work/Life Synergy in the Healthcare Industry was published in 2024.

The Mentors Radio Show
423. London-based Justin Stebbing, M.D. and his Journey of Discovery Finding Improved Therapies for Cancer

The Mentors Radio Show

Play Episode Listen Later May 3, 2025 42:26


In this episode of THE MENTORS RADIO, host Tom Loarie talks with Justin Stebbing, M.D., a London-based, world-renown scientist, cancer researcher, medical journal editor and author. Dr. Stebbing talks about the excitement and rewards of a STEM career, the life of a scientist, and about his own journey to becoming a world-renown clinician and scientist. He also about the tremendous wonder of discovering improved therapies for cancer and for treating covid. Professor Justin Stebbing, M.D., is also a professor of biomedical sciences at ARU, Cambridge, and a visiting professor at Imperial College where he has an active and widely known translational laboratory. He is the author of more than 700 peer-reviewed papers published in The Lancet, The New England Journal of Medicine and elsewhere. Dr. Stebbing is the co-chief editor of Oncogene and author of the book, Witness to Covid. Find Show Notes below. Listen to this episode below and on ANY podcast platform (from Apple to Spotify, Google, Stitcher, Spotify, TuneIn, etc) by typing in “THE MENTORS RADIO” … even easier, Subscribe HERE to listen on any podcast platform!!! SHOW NOTES: JUSTIN STEBBING, M.D.: BIO: https://www.imperial.ac.uk/people/j.stebbing AND https://justinstebbing.me/ BOOK: Witness to Covid: The diary of a global pandemic, by Professor Justin Stebbing ARTICLES: PROFESSOR JUSTIN STEBBING: The revolution that makes me believe we really CAN beat cancer in my lifetime

The HemOnc Pulse
Redirected Strategy: Tal and TEC in the Myeloma Mix

The HemOnc Pulse

Play Episode Listen Later May 2, 2025 16:51


In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial's rationale, design, and real-world implications for patients with relapsed or refractory disease. Tune in to hear expert perspectives on unmet needs in late-line myeloma care, emerging toxicity profiles, and the future of dual-targeted immunotherapy.

Rant and Rave With Becky and Erik
Another Round of Ochsner's Milk-Bank Miracles & A Homelessness Report from Council Member Lesli Harris

Rant and Rave With Becky and Erik

Play Episode Listen Later May 2, 2025 89:42


Send us a textI am truly excited about this new segment brought to ya' by Ochsner's Childrens' Hospital! Milk-Bank Miracles with Dr. Harley Ginsberg will shine light on what the NICU is and what hospitals do to keep our little, itty bitty nuggets alive! It really is miraculous.  Dr. Ginsberg is the founder and medical director of Mothers' Milk Bank of Louisiana at Ochsner Baptist. He has written chapters for medical textbooks on neonatology and has published scientific medical articles in the New England Journal of Medicine, the Journal of Perinatology, and Clinics in Perinatology among others. Dr. Ginsberg's professional interests include the use of donor human milk to prevent neonatal intestinal disease as well as the role of human milk in infection prevention.  I am blown away by this opportunity to partner with him and open a window for our audience to learn more not only about his Mother's Milk-Bank but also the guided hand to learn about the NICU! (Neonatal Intensive Care Unit.)To learn more about this go to: www.ochsner.org_______________________________________________________________________________________________Then later we welcome New Orleans Council Member Lesli Harris to hear about what our city is doing to combat our homeless crisis. I met Council Member Harris one hot and blazey summer afternoon and since then, she has graced our show with her smile and passion for our city. I was so inspired by her devotion in this area of SO MANY areas to focus on. I learned by our interview that over 200 individuals have been rehabilitated through the "Home For Good Program" (https://homeforgoodneworleans.org)                                        Over 1,000 individuals have been taken off the street and ARE GIVEN recourses in all aspects of life; not to only get them off the streets, but to give them dignity, confidence and motivation to get back up and make the next day better than the last. I wish you could see Council Member Lesli Harris' eyes when she presents the raw data, stats and numbers that really are jolting. There were a couple of topics that we didn't see quite eye to eye, but that is what civil dialogue is and unfortunately has been lost in our country for some time now.  I came to her with urgency because of a situation that happened with me and my family in the Marigny a couple of months back. It startled me, and I felt helpless. I don't like that feeling, ESPECIALLY when my babies are with me.  My fear is that if the homeless numbers don't fall, the Governor will come in without warning and sweep the city before the city council, mayor, police chief etc. can do one thing. I am encouraged by the newly released nola.com article that showed Council Member Lesli's vision. IS WORKING. And that bottom line is all I truly worry about. Her candor, smile and authenticity won me over from the beginning and I am still living for it. THANK YOU COUNCIL MEMBER HARRIS! Read the article I spoke about here,  Lesli Harris: New Orleans' homeless efforts are workingThank you to our family of amazing sponsors! Ochsner Hospital for ChildrenWww.ochsner.orgRouses MarkersWww.rousesmarkets.comSandpiper VacationsWww..sandpipervacations.comCafe Du Monde www.shop.cafedumonde.com The Law Firm of Forrest Cressy & James Www.forrestcressyjames.comComfort Cases Www.comfortcases.orgNew Orleans Ice Cream CompanyWww.neworleansicecream.comERA TOP REALTY: Pamela BreauxAudubon Institute www.auduboninstitute.orgUrban South Brewery www.urbansouthbrewery.com

CBS This Morning - News on the Go
Safest Cars for New Drivers | Nate Burleson Dives into Open Shark Water | Wilmer Valderrama Previews High-Stakes "NCIS" Season Finale

CBS This Morning - News on the Go

Play Episode Listen Later May 1, 2025 41:15


CBS News has obtained an exclusive video of a man with alleged ties to North Korean leader Kim Jong Un's regime during what he thought was an interview for a job at an American tech company. CBS News' Nicole Sganga has more. A study from the New England Journal of Medicine found new evidence that GLP-1 drugs used for diabetes and obesity could also help people with a type of liver disease. CBS News contributor Dr. Celine Gounder explains the findings. A Nashville mom and former TV meteorologist says she's the victim of an online sextortion scam. Bree Smith spoke to "CBS Mornings" about how she's fighting back after her image was doctored into explicit pictures and videos for money. It's a scam the FBI says targeted tens of thousands of Americans last year. CBS News correspondent Kris Van Cleave shares which vehicles top the list for teen driver safety, including several budget-friendly options.Wilmer Valderrama talks with "CBS Mornings" about the upcoming "NCIS" finale, his nine seasons on the hit series, and why the show continues to draw millions of viewers worldwide. In the latest "Never Too Late" feature, Nate Burleson pushes past fear once again—this time by diving into shark-infested waters to face his ocean phobia head-on.Tony winners Sarah Paulson and Wendell Pierce join "CBS Mornings" to announce this year's major nominees and share memories from their acclaimed stage performances. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

On Becoming a Healer
Emboldened Bullies Come for Medical Education

On Becoming a Healer

Play Episode Listen Later May 1, 2025 53:52


In an April 23rd executive order (EO), the president of the United States alleges that the Liaison Committee for Medical Education (LCME) and the Accreditation Council for Graduate Medical Education (ACGME) are requiring medical schools and residency programs to pursue unlawful discrimination through DEI policies. The EO calls for the US Department of Education to “assess whether to suspend or terminate” them, and to “streamline the process” for recognizing new accreditors to replace them.  In addition, medical journals, including the New England Journal of Medicine, are getting letters from a US Attorney, calling them “partisans in various scientific debates,” and requesting information.  As a follow up to our last episode on authoritarianism and its implications for the medical profession, we consider these new developments from two perspectives: On the one hand we look for evidence to support the government's claims; and, on the other, we consider how they fit into the authoritarian's playbook of capitalizing on polarization to breakdown civil society and consolidate power.  There are things physicians and other health professionals can and should be doing now – and we propose a few -- to protect our profession from an authoritarian incursion that threatens our commitment so scientific integrity, and to a medical education system that, however imperfect, is informed by expert knowledge and professional values.

The Healthcare Policy Podcast ®  Produced by David Introcaso
Johns Hopkins' Economics Prof. Melinda Buntin Discusses Slowing Healthcare Spending Growth Over the Past Two Decades

The Healthcare Policy Podcast ® Produced by David Introcaso

Play Episode Listen Later May 1, 2025 32:07


US healthcare costs and spending are extreme made evident by the fact healthcare at a $5 trillion annually accounts for roughly half the global healthcare market. This reality led Princeton's Nobel Prize Economist Angus Deaton to conclude in 2020, “the industry is a cancer at the heart of the economy.” Though healthcare costs are projected to rise 7 to 8%, this year, cost growth over the past 15 plus years plus has not on average exceeded GDP growth - made evident by the fact that while the 2020 Medicare Trustee report concluded the Medicare hospital trust fund would be bankrupt by 2026, the most recent report concluded 2036. Prof. Buntin's recent writing on the topic, “The Value Zeitgeist, Considering the Slowdown in Healthcare Spending Growth,” coauthored by Harvard's Ellen Meara and Dartmouth's Carrie Colla, was published in “The New England Journal of Medicine” on April 12th. Prof Buntin's recent publications are at: https://hbhi.jhu.edu/expert/melinda-buntin. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

The Lead Podcast presented by Heart Rhythm Society
The Lead Podcast - Episode 101: A Discussion of Pulsed Field or Cryoballoon Ablation...

The Lead Podcast presented by Heart Rhythm Society

Play Episode Listen Later May 1, 2025 9:43


Join host Prashanthan Sanders, MBBS, PhD, FHRS, and episode guests Jason G. Andrade, MD, FHRS, and Melanie Gunawardene, MD, as they discuss Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. This discussion was recorded in person at EHRA 2025 in Vienna, Austria. The article under discussion was presented at EHRA 2025 and simultaneously published in the New England Journal of Medicine.   https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2502280   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical   Contributor Disclosure(s): M. Gunawrdene: Honoraria/Speaking/Consulting: Farapulse, Abbott Medical, Boston Scientific, Medtronic, Biotronik, Luma Vision, Bristol Myers Squibb J. Andrade: Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Inc., Biosense Webster, Inc.

Always On EM - Mayo Clinic Emergency Medicine
Chapter 43 - Code Brown: When the runs run the room! - Management of Acute Diarrheal Emergencies

Always On EM - Mayo Clinic Emergency Medicine

Play Episode Listen Later May 1, 2025 59:35


Diarrhea is one of the more common concerns in emergency medicine worldwide and in the United States, yet we often do not spend enough time understanding the breadth of causes and considerations for this syndrome. Do you know which patients benefit from Zinc? Would you like to review HUS? Can you mixup Oral Rehydration Solution if you needed to? We cover all of this and more in this “code brown” of a chapter! So come, get dirty with Alex and Venk in this truly crappy chapter of Always on EM!   CONTACTS X - @AlwaysOnEM; @VenkBellamkonda YouTube - @AlwaysOnEM; @VenkBellamkonda Instagram – @AlwaysOnEM; @Venk_like_vancomycin; @ASFinch Email - AlwaysOnEM@gmail.com REFERENCES & LINKS Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, Langley JM, Wanke C, Warren CA, Cheng AC, Cantey J, Pickering LK. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):e45-e80. doi: 10.1093/cid/cix669. PMID: 29053792; PMCID: PMC5850553. Gore JI, Surawicz C. Severe acute diarrhea. Gastroenterol Clin North Am. 2003 Dec;32(4):1249-67. doi: 10.1016/s0889-8553(03)00100-6. PMID: 14696306; PMCID: PMC7127018. Freedman SB, van de Kar NCAJ, Tarr PI. Shiga Toxin–Producing Escherichia coli and the Hemolytic–Uremic Syndrome. The New England Journal of Medicine. 2023;389(15):1402-1414. doi:10.1056/NEJMra2108739. Logan C, Beadsworth MB, Beeching NJ. HIV and diarrhoea: what is new? Curr Opin Infect Dis. 2016 Oct;29(5):486-94. doi: 10.1097/QCO.0000000000000305. PMID: 27472290. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf. 2000 Jan;22(1):53-72. doi: 10.2165/00002018-200022010-00005. PMID: 10647976. Schiller LR. Secretory diarrhea. Curr Gastroenterol Rep. 1999 Oct;1(5):389-97. doi: 10.1007/s11894-999-0020-8. PMID: 10980977. Gong Z, Wang Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncol Pract. 2020 Aug;16(8):453-461. doi: 10.1200/OP.20.00002. Epub 2020 Jun 25. PMID: 32584703. Do C, Evans GJ, DeAguero J, Escobar GP, Lin HC, Wagner B. Dysnatremia in Gastrointestinal Disorders. Front Med (Lausanne). 2022 May 13;9:892265. doi: 10.3389/fmed.2022.892265. PMID: 35646996; PMCID: PMC9136014. Expert Panel on Gastrointestinal Imaging; Chang KJ, Marin D, Kim DH, Fowler KJ, Camacho MA, Cash BD, Garcia EM, Hatten BW, Kambadakone AR, Levy AD, Liu PS, Moreno C, Peterson CM, Pietryga JA, Siegel A, Weinstein S, Carucci LR. ACR Appropriateness Criteria® Suspected Small-Bowel Obstruction. J Am Coll Radiol. 2020 May;17(5S):S305-S314. doi: 10.1016/j.jacr.2020.01.025. PMID: 32370974. Rami Reddy SR, Cappell MS. A Systematic Review of the Clinical Presentation, Diagnosis, and Treatment of Small Bowel Obstruction. Curr Gastroenterol Rep. 2017 Jun;19(6):28. doi: 10.1007/s11894-017-0566-9. PMID: 28439845. Modahl L, Digumarthy SR, Rhea JT, Conn AK, Saini S, Lee SI. Emergency department abdominal computed tomography for nontraumatic abdominal pain: optimizing utilization. J Am Coll Radiol. 2006 Nov;3(11):860-6. doi: 10.1016/j.jacr.2006.05.011. PMID: 17412185. Scheirey CD, Fowler KJ, Therrien JA, et al. ACR Appropriateness Criteria Acute Nonlocalized Abdominal Pain. Journal of the American College of Radiology : JACR. 2018;15(11S):S217-S231. doi:10.1016/j.jacr.2018.09.010. Atia AN, Buchman AL. Oral rehydration solutions in non-cholera diarrhea: a review. Am J Gastroenterol. 2009 Oct;104(10):2596-604; quiz 2605. doi: 10.1038/ajg.2009.329. Epub 2009 Jun 23. PMID: 19550407. Musekiwa A, Volmink J. Oral rehydration salt solution for treating cholera: ≤ 270 mOsm/L solutions vs ≥ 310 mOsm/L solutions. Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD003754. doi: 10.1002/14651858.CD003754.pub3. PMID: 22161381; PMCID: PMC6532622. Centers for Disease Control and Prevention (CDC). Scombroid fish poisoning associated with tuna steaks--Louisiana and Tennessee, 2006. MMWR Morb Mortal Wkly Rep. 2007 Aug 17;56(32):817-9. PMID: 17703171. Résière D, Florentin J, Mehdaoui H, Mahi Z, Gueye P, Hommel D, Pujo J, NKontcho F, Portecop P, Nevière R, Kallel H, Mégarbane B. Clinical Characteristics of Ciguatera Poisoning in Martinique, French West Indies-A Case Series. Toxins (Basel). 2022 Aug 3;14(8):535. doi: 10.3390/toxins14080535. PMID: 36006197; PMCID: PMC9415704. Centers for Disease Control and Prevention (CDC). Ciguatera fish poisoning--Texas, 1998, and South Carolina, 2004. MMWR Morb Mortal Wkly Rep. 2006 Sep 1;55(34):935-7. PMID: 16943762. Thyroid Inferno EM Blog: https://emblog.mayo.edu/2014/11/01/thyroid-inferno/  Lazzerini M, Wanzira H. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2016 Dec 20;12(12):CD005436. doi: 10.1002/14651858.CD005436.pub5. PMID: 27996088; PMCID: PMC5450879. Dhingra U, Kisenge R, Sudfeld CR, Dhingra P, Somji S, Dutta A, Bakari M, Deb S, Devi P, Liu E, Chauhan A, Kumar J, Semwal OP, Aboud S, Bahl R, Ashorn P, Simon J, Duggan CP, Sazawal S, Manji K. Lower-Dose Zinc for Childhood Diarrhea - A Randomized, Multicenter Trial. N Engl J Med. 2020 Sep 24;383(13):1231-1241. doi: 10.1056/NEJMoa1915905. PMID: 32966722; PMCID: PMC7466932. Dalfa RA, El Aish KIA, El Raai M, El Gazaly N, Shatat A. Oral zinc supplementation for children with acute diarrhoea: a quasi-experimental study. Lancet. 2018 Feb 21;391 Suppl 2:S36. doi: 10.1016/S0140-6736(18)30402-1. Epub 2018 Feb 21. PMID: 29553435.   WANT TO WORK AT MAYO? EM Physicians: https://jobs.mayoclinic.org/emergencymedicine EM NP PAs: https://jobs.mayoclinic.org/em-nppa-jobs   Nursing/Techs/PAC: https://jobs.mayoclinic.org/Nursing-Emergency-Medicine EMTs/Paramedics: https://jobs.mayoclinic.org/ambulanceservice All groups above combined into one link: https://jobs.mayoclinic.org/EM-Jobs

Hijos de la Resistencia
#279 Cómo te engaña tu cerebro (y por qué funciona)

Hijos de la Resistencia

Play Episode Listen Later May 1, 2025 43:32


¿Puede un placebo mejorar tu rendimiento deportivo real, incluso si no tomaste nada? ¿Qué procesos biológicos se activan en tu cuerpo solo por creer que algo funciona? Tu cerebro puede hacerte rendir más, sentir menos dolor e incluso recuperarte antes… solo con creer que algo va a funcionar. ¿Dónde está el límite entre lo fisiológico y lo psicológico? ¿Y si la mente fuera el factor olvidado del rendimiento? _____________________________________________________ Newsletter para entrenadores: https://hijosdelaresistencia.com/para-entrenadores-que-quieren-dejar-un-legado/ ————————- Accede a la web de Fanté https://bit.ly/WebFant%C3%A9 Elige lo que prefieras: 10% descuento con el código PODCASTHDLR Acceso a regalos y formación exclusiva con el código REGALOHDLR ————————- Apúntate a nuestra Newsletter aquí: https://hijosdelaresistencia.com/un-email-semanal Entrena con nosotros: https://hijosdelaresistencia.com/formulario/ Accede a La Academia https://academia.hijosdelaresistencia.com/ ____________________________________________________________ También pueden seguirnos en nuestras redes sociales https://www.instagram.com/hijosdelaresistencia_oficial/ https://www.instagram.com/ruben.espinosa_/ ---------------------------------------------------------------------------------- Referencias científicas 1. Beecher, H. K. (1955). The powerful placebo. Journal of the American Medical Association, 159(17), 1602–1606. 2. Moseley, J. B., O'Malley, K., Petersen, N. J., Menke, T. J., Brody, B. A., Kuykendall, D. H., Hollingsworth, J. C., Ashton, C. M., & Wray, N. P. (2002). A controlled trial of arthroscopic surgery for osteoarthritis of the knee. The New England Journal of Medicine, 347(2), 81–88. 3. Beard, D. J., Rees, J. L., Cook, J. A., Rombach, I., Cooper, C., Merritt, N., ... & Carr, A. J. (2018). Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. The Lancet, 391(10118), 329–338. 4. Stone, M. R., Thomas, K., Wilkinson, M., Jones, A. M., St Clair Gibson, A., & Thompson, K. G. (2012). Effects of deception on exercise performance: Implications for determinants of fatigue in humans. Medicine & Science in Sports & Exercise, 44(3), 534–541. 5. Beedie, C. J., & Foad, A. J. (2009). The placebo effect in sports performance: a brief review. Sports Medicine, 39(4), 313–329. 6. Waber, R. L., Shiv, B., Carmon, Z., & Ariely, D. (2008). Commercial features of placebo and therapeutic efficacy. Journal of the American Medical Association, 299(9), 1016–1017. 7. Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS ONE, 5(12), e15591.

Recomendados de la semana en iVoox.com Semana del 5 al 11 de julio del 2021
#279 Cómo te engaña tu cerebro (y por qué funciona)

Recomendados de la semana en iVoox.com Semana del 5 al 11 de julio del 2021

Play Episode Listen Later May 1, 2025 43:32


¿Puede un placebo mejorar tu rendimiento deportivo real, incluso si no tomaste nada? ¿Qué procesos biológicos se activan en tu cuerpo solo por creer que algo funciona? Tu cerebro puede hacerte rendir más, sentir menos dolor e incluso recuperarte antes… solo con creer que algo va a funcionar. ¿Dónde está el límite entre lo fisiológico y lo psicológico? ¿Y si la mente fuera el factor olvidado del rendimiento? _____________________________________________________ Newsletter para entrenadores: https://hijosdelaresistencia.com/para-entrenadores-que-quieren-dejar-un-legado/ ————————- Accede a la web de Fanté https://bit.ly/WebFant%C3%A9 Elige lo que prefieras: 10% descuento con el código PODCASTHDLR Acceso a regalos y formación exclusiva con el código REGALOHDLR ————————- Apúntate a nuestra Newsletter aquí: https://hijosdelaresistencia.com/un-email-semanal Entrena con nosotros: https://hijosdelaresistencia.com/formulario/ Accede a La Academia https://academia.hijosdelaresistencia.com/ ____________________________________________________________ También pueden seguirnos en nuestras redes sociales👇🏻https://www.instagram.com/hijosdelaresistencia_oficial/ https://www.instagram.com/ruben.espinosa_/ ---------------------------------------------------------------------------------- 📚 Referencias científicas 1. Beecher, H. K. (1955). The powerful placebo. Journal of the American Medical Association, 159(17), 1602–1606. 2. Moseley, J. B., O'Malley, K., Petersen, N. J., Menke, T. J., Brody, B. A., Kuykendall, D. H., Hollingsworth, J. C., Ashton, C. M., & Wray, N. P. (2002). A controlled trial of arthroscopic surgery for osteoarthritis of the knee. The New England Journal of Medicine, 347(2), 81–88. 3. Beard, D. J., Rees, J. L., Cook, J. A., Rombach, I., Cooper, C., Merritt, N., ... & Carr, A. J. (2018). Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. The Lancet, 391(10118), 329–338. 4. Stone, M. R., Thomas, K., Wilkinson, M., Jones, A. M., St Clair Gibson, A., & Thompson, K. G. (2012). Effects of deception on exercise performance: Implications for determinants of fatigue in humans. Medicine & Science in Sports & Exercise, 44(3), 534–541. 5. Beedie, C. J., & Foad, A. J. (2009). The placebo effect in sports performance: a brief review. Sports Medicine, 39(4), 313–329. 6. Waber, R. L., Shiv, B., Carmon, Z., & Ariely, D. (2008). Commercial features of placebo and therapeutic efficacy. Journal of the American Medical Association, 299(9), 1016–1017. 7. Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS ONE, 5(12), e15591.

The Steve Harvey Morning Show
Uplift: She's creating solutions to address health inequities amongst Black Families living in the South.

The Steve Harvey Morning Show

Play Episode Listen Later Apr 29, 2025 39:53 Transcription Available


Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSupport the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Strawberry Letter
Uplift: She's creating solutions to address health inequities amongst Black Families living in the South.

Strawberry Letter

Play Episode Listen Later Apr 29, 2025 39:53 Transcription Available


Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSee omnystudio.com/listener for privacy information.

Best of The Steve Harvey Morning Show
Uplift: She's creating solutions to address health inequities amongst Black Families living in the South.

Best of The Steve Harvey Morning Show

Play Episode Listen Later Apr 29, 2025 39:53 Transcription Available


Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSteve Harvey Morning Show Online: http://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Dear Infertility: Finding Calm When Trying Is Trying
BV as an STI?, Period Flow Red Flags, & Katherine's Rare Pregnancy Diagnosis

Dear Infertility: Finding Calm When Trying Is Trying

Play Episode Listen Later Apr 29, 2025 37:04


In this episode of From First Period to Last Period, Katherine shares her emotional and unexpected story: a molar pregnancy that led to cancer treatment. It's a powerful reminder of how complex and unpredictable reproductive health can be — and why these conversations matter.Kristyn and Dr. Jenna Kahn also tackle some of your most Googled questions: BV vs. UTI — what's the real difference, and why does it matter? How heavy is too heavy when it comes to your period? And, what's the deal with intermittent fasting — helpful or hype? Our friend Anna Bohnengel, RDN, breaks this one down. Plus, we dive into a groundbreaking new study in The New England Journal of Medicine that's changing the way we think about BV: treating male partners too could reduce recurrence by over 50%. Could BV actually be sexually transmitted after all?Hit play now on Spotify, Apple Podcasts, YouTube, or wherever you listen!

The Secret Teachings
Fear and Loathing in the Pandemic w. Ryder Lee (4/24/25)

The Secret Teachings

Play Episode Listen Later Apr 24, 2025 120:01


The scientific method involves observation, questioning, forming hypotheses, testing predictions and altering theories to align with results; it is not the altering of results to align with a hypothesis.  There are three acceptable narratives about COVID-19: a wet mart (official), 5G (conspiracy), and laboratory leak (alternative). Whereas the https://www.science.org/content/article/cia-bribed-its-own-covid-19-origin-team-reject-lab-leak-theory-anonymous-whistleblower to reject the lab theory, https://apnews.com/article/covid-cia-trump-china-pandemic-lab-leak-9ab7e84c626fed68ca13c8d2e453dde1 explanation. This announcement was made just days after the former President regained the White House. As of April 2025, the https://www.whitehouse.gov/lab-leak-true-origins-of-covid-19/?fbclid=IwY2xjawJv5wdleHRuA2FlbQIxMAABHrhaCm1LYQx2UbG8uGLw5gkhCvB3N4a2gNrAgdarT7Z6C-XKZijSXHb3PctU_aem_hUJWc6XJ_Gfj14AvDa1VSA as “the true origins of COVID-19.”  This new official designation means that at one time or another two totally different explanations were given, ultimately with the consequence of censorship and ridicule if a person thought or said anything different. Both explanations still result in justufciaotn for past, and future, measures such as: social distancing, masking, https://www.theatlantic.com/ideas/archive/2021/04/end-hygiene-theater/618576/ as a form of a theater, vaccines, etc.  Prior to the recent shift in narratives, undercover video reportedly proved that Pfizer was indeed conducing gain of function research in a laboratory. But that lab was not a viral facility or a Wuhan institute; instead, it was a computer lab. In fact, https://www.pfizer.com/news/announcements/pfizer-responds-research-claims stating: “With a naturally evolving virus, it is important to routinely assess the activity of an antiviral. Most of this work is conducted using computer simulations…” Such computer simulations were used to predict mass casualties from COVID, too, and are the same ones being employed for Climate Change narratives. But what is COVID-19 or the virus designated SARS-COV-2. It is a list or complex of symptoms that are classified into categories of disease. Examination of COVID's symptoms prove they are nearly identical to the common cold and flu, among others. In fact, the https://hsph.harvard.edu/news/a-sharp-drop-in-flu-cases-during-covid-19-pandemic/. According to Harvard, this was the result of “wearing masks and distancing,” though they did not explain how such measures stopped the flu but not SARS-COV-2. Consider these three sets of symptoms from the CDC website: https://www.cdc.gov/common-cold/about/index.html: runny nose or nasal congestion, cough, sneezing, sore throat, headache, mild body aches, fever.https://www.cdc.gov/flu/signs-symptoms/index.html: runny or stuffy nose, cough, sore throat, headaches, muscle or body aches, fatigue, fever, and vomiting or diarrhea.  https://www.cdc.gov/covid/signs-symptoms/index.html: congestion or runny nose, cough, sore throat, headache, muscle or body aches, fatigue, fever or chills, nausea or vomiting, and diarrhea.  The only distinct symptoms of COVID were “shortness of breath or difficulty breathing” and “new loss of taste or smell.” The first symptom is already https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm in the United States - chronic lower respiratory disease. Since COVID was first tested CLRD has been bumped to sixth, though many of these respiratory deaths have been listed as COVID. In other words, what would have been diagnosed as CLRD was categorized instead as COVID-19. This is the same reason flu nearly disappeared as reported cases. These breathing problems were, within the COVID diagnosis, themselves sub-categorized as COVID-Pneumonia, and https://my.clevelandclinic.org/health/diseases/24002-covid-pneumonia.   The second symptom of losing a senes of taste or smell varied between total loss and partial loss, something that also occurs with the common cold and flu. This distinct and often promoted https://www.healthline.com/health-news/who-is-most-likely-to-lose-their-sense-of-smell-and-taste-from-covid-19, and even so only involved some often minor or unspecified form of loss.  Thus we can determine that between 15-37% of COVID cases had “distinct” symptoms arguably different than the overall symptoms that classify cold or flu, which means at liberal estimates over two thirds of COVID cases were nothing more than a case of the cold or flu. When defining what caused these other symptoms, we know recategorized pneumonia was one. But what about other causes that resulted in loss of senses?  Other than injuries or inflammation, often caused by what we call allergies, https://www.livestrong.com/article/13731552-food-suddenly-tastes-different/ and https://pubmed.ncbi.nlm.nih.gov/27178656/, as can neurological disorders. Other than the obvious and physical, there is also the psychological. Anxiety and stress are well known to alter sense perceptions, including https://www.calmclinic.com/anxiety/signs/smell and https://pmc.ncbi.nlm.nih.gov/articles/PMC10668578/. Consider how much anxiety and stress were cultivated by 24-hour coverage of cases, deaths, symptoms, videos from China, etc., and how wiling the public was to adopt any perceptually legal or even illogical dictate for the purposes of keeping themselves and others “safe.” There is a long history of such mass psychogenic pathogen.Much of this fear was generated by variant names like “KRAKEN,” a mythical monster, as was https://www.unmc.edu/healthsecurity/transmission/2023/09/19/meet-the-man-who-named-covids-new-variants/ who likewise believed this naming heightened the public's perception of a terror they should be feeling. Such fear became so intense that one analysis suggested that COVID activated “archetypes of evil” and thus “added psychological suffering.” The study suggested: “Fear and grief caused by the pandemic have produced a powerful unconscious narrative in the collective psyche that the coronavirus is driven by an https://pmc.ncbi.nlm.nih.gov/articles/PMC8441919/. The resulting archetypal dimension of fear causes an extra layer of psychological suffering in individuals.”  Such mythical, theological, and even magical terms were not lost in the New England Journal of Medicine which openly declared in 2020 that masks were little more than talismans: “Masks are not only tools, https://www.nejm.org/doi/full/10.1056/NEJMp2006372...” A spirit or demon possessing a body is an impure form that makes one sick. Items such as crosses or holy water are employed in its exorcism - to exercise/exorcise the demon and make healthy again - along with the name of the unclean. The same is done today in modern vaccine administration. The holy water is replaced by a vaccine vial, the cross is replaced by a syringe and plunger, the demon's name is replaced by the variant or virus name, and the ritual robes are replaced by white lab coats.  The pandemic was not about a virus and a distinct set of symptoms. Instead it was about inducing archetypical fear and https://www.weforum.org/stories/2020/10/the-rich-got-richer-during-the-pandemic-and-that-s-a-daunting-sign-for-our-recovery/. It was at best https://www.history.com/articles/mysterious-illnesses-mass-hysteria, in the middle a conspiracy of fraud and psychological terror, and at worst a dark magical ritual to induce trauma.  Further evidence of the fraud can be found in reports like this one from the New York Times that discuss the ultra amplification of PCR testing cycles from the low 30s to the mid 40s -“https://absa.org/wp-content/uploads/2020/09/NYT-200829-Your-Coronavirus-Test.pdf” - “In three sets of testing data that include cycle thresholds, compiled by officials in Massachusetts, New York and Nevada, up to 90 percent of people testing positive carried barely any virus…In Massachusetts, from 85 to 90 percent of people who tested positive in July with a cycle threshold of 40 would have been deemed negative if the threshold were 30 cycles.”  Even ‘true' positive tests do not indicate symptoms or disease, or the future development of such, which brings us back to the White House website and the statement about the lab leak: “The virus possesses a biological characteristic that is not found in nature.” This may be true, as per whatever is being assumed to exist, or observed under a microscope, or played with in a computer model, yet it does not prove any disease, especially in https://abcnews.go.com/Health/covid-transmission-asymptomatic/story?id=84599810. *The is the FREE archive.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

The Itch: Allergies, Asthma & Immunology
#109 - Tezepelumab & Nasal Polyps: Inside the WAYPOINT Phase III Trial

The Itch: Allergies, Asthma & Immunology

Play Episode Listen Later Apr 24, 2025 27:31


Have you wondered why having more drug options matters for chronic rhinosinusitis with nasal polyps? In the inaugural episode of our new series, The Itch Review, co-hosts Kortney and Dr. Payel Gupta, along with special guest Dr. Michael Blaiss, unpack the journal article "Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps," published in the New England Journal of Medicine on March 1, 2025. This article is about the Phase III WAYPOINT trial of tezepelumab. Already approved for severe asthma, this once-monthly biologic is now showing promise in chronic rhinosinusitis with nasal polyps (CRSwNP). Over 52 weeks, 408 patients were randomized to receive 210 mg of tezepelumab every four weeks or placebo. Researchers tracked nasal-polyp scores, congestion, sense of smell, and rates of rescue surgery. In this episode, we provide a brief overview of what CRSwNP is, why inflammation drives polyp formation and how blocking TSLP fits into today's biologics options. We'll walk you through the WAYPOINT Phase III design, explain the primary and secondary endpoints, and translate the headline results into what they mean for real-world patients who've exhausted their treatment options. ➡️ Get the infographic here. What we cover in our episode about treating chronic rhinosinusitis with nasal polyps with tezepelumab CRSwNP basics & tezepelumab mechanism of action: How nasal polyps form and why targeting TSLP can reduce inflammation WAYPOINT design: 52-week, placebo-controlled Phase III study in 408 patients  Primary endpoints: Mean change in nasal polyp score and nasal-congestion score Secondary endpoints: Smell recovery, need for rescue surgery or systemic steroids, and quality-of-life measures Why choice matters: Every CRSwNP patient responds differently, and having more treatment options means more chances to find the right fit   Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

CLOT Conversations
Reduced-Dose Apixaban for Cancer-Associated Thrombosis: A New Standard?

CLOT Conversations

Play Episode Listen Later Apr 24, 2025 15:36


Send us a textIn this episode of CLOT Conversations, we sit down with Dr. Marc Carrier to explore a groundbreaking study published in the New England Journal of Medicine on reduced-dose apixaban for cancer-associated venous thromboembolism (VTE). Dr. Carrier breaks down the study's findings, which suggest that a lower dose of apixaban after six months of treatment is just as effective in preventing clot recurrence — and significantly safer in terms of bleeding risk. Tune in for expert insights on how this data could shift clinical practice and improve outcomes for patients living with cancer.Reference:Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, López-Núñez JJ, Otero-Candelera R. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. New England Journal of Medicine. 2025 Mar 29.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

The Peds NP: Pearls of Pediatric Evidence-Based Practice

Welcome to the Choosing Wisely Campaign series! This 6-part series will explore the ABIM Foundation's Choosing Wisely Campaign, its historical precedent, and its goals. We will discuss how this initiative aims to promote conversations between clinicians and patients to avoid unnecessary medical tests, treatments, and procedures. The introduction episode dives into the historic 2010 editorial in the New England Journal of Medicine that inspired over 80 professional societies to write their “Top 5 Lists” of tests and procedures that could be avoided in evidence-based care. To better understand the problem, we then pick apart the survey that provided insight into why we over order and the harm it causes to vulnerable populations.  In the coming episodes, we'll explore the pediatric lists and apply our knowledge to cases of common presentations seen in primary and acute care pediatrics.  Author: Becky Carson, DNP, APRN, CPNP-PC/AC www.thepedsnp.com Instagram: @thepedsnppodcast Series Learning Objectives: Introduction to the Choosing Wisely Campaign: Understand the origins, historical precedent, and primary goals of the campaign. Case-Based Applications: Explore five common presentations in primary and acute care pediatrics, applying concepts from various Choosing Wisely lists to guide management and resource stewardship. Effective Communication: Learn strategies for engaging in tough conversations with parents and colleagues to create allies and ensure evidence-based practices are followed. Competencies: AACN Essentials: 1: 1.1 g, 1.2f 2: 2.1 de, 2.2g, 2.5 ij 6: 6.1 i 7: 7.2 ghk 9: 9.1ij, 9.2ij, 9.3ik NONPF NP Core Competencies: 1: NP1.1h, NP 1.2km 2: NP2.1jg, NP2.2kn, NP2.5 lo 6: NP6.1o 7: NP7.2m 9: NP9.1mn, NP9.2n, NP9.3p Modified rMETRIQ Score: 15/15 Learn more about our peer review process at www.thepedsnp.com/peerreview   References: ABIM Foundation. (2019). Communicating about overuse with vulnerable populations. Retrieved from https://www.choosingwisely.org/files/Communicating-About-Overuse-to-Vulnerable-Population_Final2.pdf Brody, H. (2010). Medicine's ethical responsibility for health care reform--the Top Five list. The New England journal of medicine, 362(4), 283–285. https://doi.org/10.1056/NEJMp0911423 Lipitz-Snyderman, A., & Bach, P. B. (2013). Overuse of health care services: when less is more … more or less. JAMA internal medicine, 173(14), 1277–1278. https://doi.org/10.1001/jamainternmed.2013.6181 PerryUndem Research/Communication. (2014). Unnecessary tests and procedures in the health care system. Retrieved from https://www.choosingwisely.org/files/Final-Choosing-Wisely-Survey-Report.pdf Smith-Bindman, R., Chu, P. W., Azman Firdaus, H., Stewart, C., Malekhedayat, M., Alber, S., Bolch, W. E., Mahendra, M., Berrington de González, A., & Miglioretti, D. L. (2025). Projected Lifetime Cancer Risks From Current Computed Tomography Imaging. JAMA internal medicine, e250505. Advance online publication. https://doi.org/10.1001/jamainternmed.2025.0505 Wyman, O. (2019). Right Place, Right Time: Health Information & Vulnerable Populations. https://www.oliverwyman.com/RightPlaceRightTime.html  

Neurology® Podcast
BTK Inhibitors in Multiple Sclerosis Treatment

Neurology® Podcast

Play Episode Listen Later Apr 21, 2025 21:03


Dr. Justin Abbatemarco talks with Dr. Jiwon Oh about Bruton Tyrosine Kinase (BTK) Inhibitors and the recent data on tolebrutinib in multiple sclerosis. Read the related article on Tolebrutinib versus Teriflunomide in The New England Journal of Medicine. Read the related article on Tolebrutinib in Nonrelapsing Secondary Progressive MS in The New England Journal of Medicine. Disclosures can be found at Neurology.org. 

Diabetes Connections with Stacey Simms Type 1 Diabetes
In the News.. GLP-1 for T1D trials, Ozempic pill, Dexcom 15-day sensor, type 5 diabetes, and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Apr 18, 2025 7:39


It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it's not approved for T1D and so insurers won't usually cover it.   https://clinicaltrials.gov/study/NCT06914895 XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there's little information on the drugs' safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can't make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1.   For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what's really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html   XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA.  Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA's caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. https://tcoyd.org/petition/ XX Dexcom receives FDA approval for it's G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says    “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.   https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long   XX Glucotrack is joining something called  FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.   The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms.     Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr   XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, Illinois.     The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. https://www.news-medical.net/news/20250414/Digital-lifestyle-program-cuts-diabetes-risk-by-4625-in-prediabetics-study-of-130k2b-adults-reveals.aspx XX Chrissy Teigan is speaking out about her son's type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes.   Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!”   Teigen shared her family's story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles' diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” https://www.fiercepharma.com/marketing/sanofi-signs-chrissy-teigen-diabetes-screening-campaign XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein's Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”.  He practiced and saw patients right up until his death.

How to Be Awesome at Your Job
1050: How to Shift Your Mood and Keep Your Cool with Dr. Ethan Kross

How to Be Awesome at Your Job

Play Episode Listen Later Apr 17, 2025 36:59


Ethan Kross shares simple, science-backed tools for managing your emotions. — YOU'LL LEARN — 1) When avoidance is actually helpful 2) Effortless strategies for quickly shifting your mood 3) The emotional regulation framework used by the Navy SEALs Subscribe or visit AwesomeAtYourJob.com/ep1050 for clickable versions of the links below. — ABOUT ETHAN — Ethan Kross, PhD, author of the national bestseller Chatter, is one of the world's leading experts on emotion regulation. An award-winning professor in the University of Michigan's top ranked Psychology Department and its Ross School of Business, he is the Director of the Emotion and Self-Control Laboratory. Ethan has participated in policy discussion at the White House and has been interviewed about his research on CBS Evening News, Good Morning America, Anderson Cooper Full Circle, and NPR's Morning Edition. His research has been featured in The New York Times, The Wall Street Journal, The New Yorker, The New England Journal of Medicine, and Science. He completed his BA at the University of Pennsylvania and his PhD at Columbia University.• Book: Shift: Managing Your Emotions--So They Don't Manage You • Book: Chatter: The Voice in Our Head, Why It Matters, and How to Harness It • Study: “Remotely administered non-deceptive placebos reduce COVID-related stress, anxiety, and depression” with Darwin A. Guevarra, Christopher T. Webster, Jade N. Moros, and Jason S. Moser • Website: EthanKross.com — RESOURCES MENTIONED IN THE SHOW — • Book: The Lincoln Letter: A Peter Fallon Novel (Peter Fallon and Evangeline Carrington) by William Martin • Book: Emotional Agility: Get Unstuck, Embrace Change, and Thrive in Work and Life by Susan David • Book: Man's Search for Meaning by Viktor Frankl • Book: The Amazing Adventures of Kavalier & Clay: A Novel by Michael Chabon • Past episode: 023: The Power of Workplace Humor with Michael KerrSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Simulcast
202 Safer Births NEJM with Hege Ersdal and Benjamin Kamala

Simulcast

Play Episode Listen Later Apr 13, 2025 41:07


Welcome to Simulcast! In this special episode, Victoria Brazil is joined by Hege Ersdal and Benjamin Kamala, the joint first authors of a ground-breaking study just published in the New England Journal of Medicine. Their program aimed to reduce birth-related mortality in Tanzania, with spectacular success. The Safer Births Bundle integrated key elements: innovative simulation training, data-driven quality improvements, advanced clinical devices, and international collaboration and local empowerment. Neonatal mortality was reduced by 40 % and maternal deaths reduced by 75%. Congratulations to all involved.  The article:  Kamala BA, Ersdal HL, Moshiro RD, Guga G, Dalen I, Kvaløy JT, Bundala FA, Makuwani A, Kapologwe NA, Mfaume RS, Mduma ER, Mdoe P; Safer Births Bundle of Care Study Group. Outcomes of a Program to Reduce Birth-Related Mortality in Tanzania. N Engl J Med. 2025 Mar 13;392(11):1100-1110. doi: 10.1056/NEJMoa2406295. 

Surfing the Nash Tsunami
S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment

Surfing the Nash Tsunami

Play Episode Listen Later Apr 13, 2025 24:34


This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He points to efruxifermin's 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug's duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin's publication of data in the New England Journal of Medicine and efimosfermin's promising data based on monthly dosing. Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies. 

Rant and Rave With Becky and Erik
Learning More About Ochsner's Milk Bank of Louisiana & A Local Documentary's Hollywood Award!

Rant and Rave With Becky and Erik

Play Episode Listen Later Apr 11, 2025 98:03


Send us a textThis week we have a couple of great Local interviews! Ochsner Children's Hospital has been one of our anchoring sponsors for years now and for our fifth season, We have created a BRAND NEW SEGMENT called         "A Mother's Giving: & the Milk Bank of Louisiana with Dr. Harley Ginsberg."Dr. Ginsberg is board certified in both pediatrics and neonatal-perinatal medicine and has been on staff at Ochsner since 1987. He served as both the Section Head of neonatal medicine at Ochsner and the Medical Director of the neonatal intensive care unit (NICU) at Ochsner Baptist Medical Center from 1989 until 2021. Dr. Ginsberg managed the team at Ochsner that took care of babies during Hurricane Katrina. Currently he is Medical Director of the NICU at Ochsner Kenner Medical Center. Dr. Ginsberg is the Founder and Medical Director of Mothers Milk Bank of Louisiana at Ochsner Baptist and is a member of the Standards Committee for the Human Milk Banking Association of North America. He has written chapters for medical textbooks on neonatology and has published scientific medical in articles in the New England Journal of Medicine, Pediatrics, Journal of Perinatology and Clinics in Perinatology. Fully accredited by the Human Milk Banking Association of North America, Mothers' Milk Bank of Louisiana at Ochsner Baptist was Louisiana's first human milk bank and the 24th nonprofit milk bank in the United States. Preterm infants are at risk for a condition called necrotizing enterocolitis, which results in inflamed intestines, bacterial infection and damage to the colon and intestines. Without proper care, the infant may die.Pasteurized donor human milk helps offset these potential dangers. Unfortunately, some mothers of preterm infants cannot produce their own milk. That's where Mothers' Milk Bank of Louisiana steps in.As of August 2020, Louisiana provides Medicaid coverage for using pasteurized donor human milk in a hospital. In 2022, Louisiana legislators approved inpatient and outpatient coverage for pasteurized donor human milk. Listen as Dr. Ginsberg and I dive into the Milk bank of Louisiana and hear the powerful impacts it has on our community and state! Go to https://www.ochsner.org/services/mothers-milk-bank-at-ochsner-baptist to learn more or to make a donation today!______________________________________________________________________________________________Then later we welcome back DIRTY DOGS! The local documentary making big waves in our city yall. Not only did the documentary chronicle the heated monopoly on New Orleans' food cart licenses for the French Quarter. What WAS a half century monopoly was essentially ended by a group of passionate film makers that felt convicted to MAKE THINGS RIGHT.  I am so excited to welcome restauranteur and host Brad Bohannan and Cinematographer, Adrian Sosebee to talk about their HOLLYWOOD AWARD they just received in  Beverly Hills! Brad also talks to us about his latest venture with his inspirational wife, Jefferson Parrish Council Person, Arita Bohannan. Together and with a village behind them, they work to bring inclusive and autistic friendly playgrounds to neighborhoods and communities tThank you to our family of amazing sponsors! Ochsner Hospital for ChildrenWww.ochsner.orgRouses MarkersWww.rousesmarkets.comSandpiper VacationsWww..sandpipervacations.comCafe Du Monde www.shop.cafedumonde.com The Law Firm of Forrest Cressy & James Www.forrestcressyjames.comComfort Cases Www.comfortcases.orgNew Orleans Ice Cream CompanyWww.neworleansicecream.comERA TOP REALTY: Pamela BreauxAudubon Institute www.auduboninstitute.orgUrban South Brewery www.urbansouthbrewery.com

biobalancehealth's podcast
Getting Old and Frail? Getting Frail MEANS Getting Old

biobalancehealth's podcast

Play Episode Listen Later Apr 8, 2025 16:01


See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog Do you ache all over? Are you weaker every year? Shorter and more bent over?   Are your clothes hanging off your shoulders? Do you walk slower and hold on to things as you walk? If you notice these signs in yourself or someone you love it means you, or they are becoming frail. As a physician I had to become a people watcher…. or more accurately an observer of the people around me.  Even if you aren't medical people, I am sure many of you are as well…. but being very observant is a requirement for a physician because there are many signs of illness that can be observed just from observing a patient who we I am treating.  I always pay attention to how the patient I am consulting with walks, shakes my hand (their strength), and how well they care for themselves, the quality of their speech, whether they look well nourished, over-nourished or frail.  All of these individual observations and more, become automatic to me as a doctor. They help me diagnose and treat my patients without a stethoscope or even an x-ray… Today I want to talk about frailty, what it is, and what it means to your doctor and you as a patient. Frailty can be defined as the visible qualities of loss of muscle mass, bone mass, energy, as and strength, as well as thinning of the skin, kyphosis of the spine (standing with your head looking down and your shoulders rounded), slow movements, weakness of strength and voice.  Frailty is the visible sign of aging. The opposite of Frailty is the Quality of being robust. When we are young we are strong, energetic, our muscles are visible, our skin is clear and taught, our posture is straight and we appear healthy and strong….when we are young we are Robust!   Frailty is the quality of being old and weak, in a catabolic state (or a state of tissue breakdown and “shrinking”).  You can equate Frailty with aging, or physically being old. What does frailty mean to a doctor? When we take care of a patient who comes to us for the first time in a frail state we rule in or out a list of diseases of aging and physical problems. These include: Arthritis Osteoporosis Sarcopenia or severe loss of muscle mass and strength Inflammatory diseases like arthritis Heart disease Diabetes Dementia Inability to be independent Doctors must look for illness and decide on a treatment to remedy a disease, but frailty is not considered a disease that has a treatment.  It is a sign that a patient is going through the last stage of life.  Many studies have been done that equate frailty to a limited life span and a loss of quality of life, but no treatment has been employed by mainstream medicine to delay, avoid or treat frailty. Up to now this is all very depressing, however it is my well founded belief that the loss of testosterone  after age 45 in women and 55 in men is the first step toward frailty, however if  adequate testosterone is replaced soon after the symptoms of T deficiency starts, then frailty can be avoided as we age, and the eventuality of loss of quality of life will be delayed or avoided all together.  It is a fact that nothing other than the hormone testosterone can reverse frailty and stop it from progressing. With T treatment my patients increase their muscle mass, create stronger muscles, and improved their mental and physical stamina. To me this is such an easy one-hormone-answer to actually improve my patients lives, at any stage in the aging process, however the pharmaceutical companies that control American medicine much prefer to treat each symptom with a different drug.  There are millions of aging folks in nursing homes who could have maintained their independence, and avoided the use of many drugs if they were treated with testosterone before their frailty reduced their mobility so they need help to perform daily activities of living independently. Sadly, medicine in the US basically gives up on frail and aging patients and we doctors are taught to make frail patients “comfortable”, just treating their symptoms without hope of reversing frailty and the outcomes of that condition.  Of course, it is much healthier to prevent frailty by replacing the essential hormone testosterone early on, however your doctor will have to think out of the box to arrive at the Testosterone treatment, rather than follow the medical protocols that involve just keeping aging patients “comfortable”. Research studies and articles to be read by doctors like the recent one in the New England Journal of Medicine that draws a direct line between aging and frailty, but only concentrates on the fact that frailty portends early death and discussed the best ways to make patients comfortable dictated by the severity of frailty.  There is no treatment other than high protein diet and vitamins with physical therapy which will not “treat” this disease. I want to tell you about two very different patients in my practice.  The first is a very successful man in his late 70s who came to me seeking weight loss because he had been an athlete and still enjoyed playing golf, but he was complaining of weakness and other symptoms of frailty, in addition to looking borderline frail when he first came to me.  We did a body composition test, and he had a higher fat mass and a lower that ideal muscle mass which is the way frailty begins. We discussed the fact that weight loss (fat loss) obtained by more exercise and less carbohydrate in his diet might improve his Pre-diabetes and inflammation, but would not make him stronger, or increase his physical and mental stamina, in other words reverse his beginning frailty.  He chose to embark on an exercise-based weight loss program combined with a high protein low carb diet. In the end he did not take my advice about the best way to lose weight without losing muscle which would have been to add Testosterone and Metformin to his treatment plan, however he wanted to be the one directing his own care (he was a business man and not a doctor) without a basic knowledge of physiology, or  nutrition, or any training about aging and frailty. Let me note that if he was younger than 55, and he tried this weight loss program while he was making adequate Testosterone, he might have had a successful fat loss program and gained muscle density and strength while he lost fat, however, this gentleman is 78. You can guess the end of the story.  He did lose weight, however he lost as much muscle as fat and was even weaker after 6 months.  This is sometimes what happens when very successful people in one area of life think that makes them brilliant in all disciplines. Now, the flipside of the coin.  I will tell you about an 82-year-old doctor who came to me almost too late.  His much younger wife was already my patient, and she encouraged him to have a consult with me to see what I could do for him.  He had the right attitude, but was already frail, and I could feel the humorous bone of his arm, when I ushered his into my office for his consultation.  I explained what observing him and his lab told me more while he told me that he had almost every symptom of aging, and frailty.  He told me that he was an athlete in college and that he always had a lot of muscle, and he watched every day as his muscles “melted away”, despite his exercise daily.  He was frustrated and had trouble with his memory as well because he had lost his testosterone long ago and he had done well for as long as he had because he had eaten a nutritious diet, taken supplements and worked out daily. We discussed his other medical problems, and some treatments for them, additional supplements to assist in building muscle and bone strength. He came back 5 months later after he had his T pellets inserted and he walked in with confidence, and the difference in his muscle mass was visible!  He was no longer “frail looking”.  He told me he was thinking better, not completely yet, but his mind was getting progressively better.  He had lost fat and gained muscle. He had turned the clock back 15 or more years.  Testosterone in the right dose and delivery system can erase frailty and give a quality of life back to my patients who had no help from other doctors. Look around you if you aren't yet at the age that carries with it frailty  or if you are without Testosterone and are experiencing frailty…look at those around you in the doctor's office or when you are waiting to board a plane…look at the pre-borders who can't walk the length of the ramp to the airplane and see if they have the visible characteristics I am talking about.   If you are over 45 and female or 55 and male and not on Testosterone maybe you should consider having your testosterone replaced so you can keep your muscle mass and independence as long as you live.

The Retirement Wisdom Podcast
Shift – Ethan Kross

The Retirement Wisdom Podcast

Play Episode Listen Later Apr 7, 2025 38:09


You're working on your physical fitness, but how about your emotional fitness? Dr. Ethan Kross visits with us to discuss his new book Shift: Managing Your Emotions -- So They Don't Manage You.  Ethan Kross joins us from Michigan. _______________________ Bio Ethan Kross, PhD, is one of the world's leading experts on emotion regulation. An award-­winning professor in the University of Michigan's top-­ranked Department of Psychology and its Ross School of Business, he is the director of the Emotion & Self Control Laboratory. Ethan has participated in policy discussions at the White House, spoken at TED and SXSW, and consulted with some of the world's top executives and organizations. He has been interviewed on CBS Evening News, Good Morning America, Anderson Cooper Full Circle, and NPR's Morning Edition. His pioneering research has been featured in The New York Times, The New Yorker, The Wall Street Journal, USA Today, The New England Journal of Medicine, and Science. He completed his BA at the University of Pennsylvania and his PhD at Columbia University. ______________________ For More on Ethan Kross Shift: Managing Your Emotions--So They Don't Manage You Website ______________________ Podcast Conversations You May Like Thinking Better to Live Better – Dr. Woo-kyoung Ahn Self-Compassion – Dr. Kristin Neff The Mindful Body – Ellen Langer Happier Hour – Cassie Holmes, PhD ________________________ Mentioned in This Podcast Episode Chatter & Your Inner Voice – Ethan Kross WOOP - Gabriele Oettingen Implementation Intentions - Peter Gollwitzer _________________________ About The Retirement Wisdom Podcast There are many podcasts on retirement, often hosted by financial advisors with their own financial motives, that cover the money side of the street. This podcast is different. You'll get smarter about the investment decisions you'll make about the most important asset you'll have in retirement: your time. About Retirement Wisdom I help people who are retiring, but aren't quite done yet, discover what's next and build their custom version of their next life. A meaningful retirement doesn't just happen by accident. Schedule a call today to discuss how The Designing Your Life process created by Bill Burnett & Dave Evans can help you make your life in retirement a great one – on your own terms. About Your Podcast Host  Joe Casey is an executive coach who also helps people design their next life after their primary career and create their version of The Multipurpose Retirement.™ He created his own next chapter after a twenty-six-year career at Merrill Lynch, where he was Senior Vice President and Head of HR for Global Markets & Investment Banking. Today, in addition to his work with clients, Joe hosts The Retirement Wisdom Podcast, which thanks to his guests and loyal listeners, ranks in the top 1 % globally in popularity by Listen Notes, with over 1.6 million downloads. Business Insider has recognized Joe as one of 23 innovative coaches who are making a difference. He's the author of Win the Retirement Game: How to Outsmart the 9 Forces Trying to Steal Your Joy. Connect on LinkedIn _________________________ Wise Quotes On Emotions "Emotions are responses to things that happen in the world or in our minds that we judge to be meaningful. And when we perceive meaningful things, it activates a loosely coordinated response within our minds and our bodies that is designed to help us manage the situations we find ourselves in. So just to make that concrete, if my view of what is right versus wrong is violated, and there's an opportunity for me to fix a situation, I'm going to experience anger. Anger is an emotion that motivates me to approach, get in there and try to fix the situation. If there's a threat on the horizon that is important to me, I'm going to experience some anxiety. I'm going to have a fight or flight response that's going to motivate me to zo...

Critical Matters
AI in Critical Care

Critical Matters

Play Episode Listen Later Mar 27, 2025 61:00


In this episode, Dr. Sergio Zanotti explores one of medicine's fastest-evolving frontiers: artificial intelligence (AI). From predictive analytics to decision-support tools, AI is beginning to influence how we deliver critical care — but what does that actually mean for frontline clinicians? Dr. Zanotti is joined by Dr. Sharad Patel, a critical care physician with additional board certification in nephrology and Echocardiography. He is a Critical Care Intensivist at Cooper University Health Care, the assistant program Director for the Internal Medicine Residency Program, and an Assistant Professor of Medicine at Cooper Medical School of Rowan University. Dr. Patel is deeply interested in applying artificial intelligence and technology at the bedside. Additional resources: Landing page for New England Journal of Medicine – AI in Medicine section. A multitude of articles and resources on the topic: https://www.nejm.org/ai-in-medicine Attention Is All You Need. A Vaswani et al. NIPS 2017: https://proceedings.neurips.cc/paper_files/paper/2017/file/3f5ee243547dee91fbd053c1c4a845aa-Paper.pdf Artificial Intelligence Courses Online: https://www.coursera.org/courses?query=artificial%20intelligence UDEMY landing page for AI courses. https://www.udemy.com/AI Books mentioned in this episode: Meditations. By Marcus Aurelius (Author), Gregory Hayes (Translator): https://amzn.to/4iLvfLA Thinking Fast and Slow. By Daniel Kahneman: https://bit.ly/4c6pANu

Frankly Speaking About Family Medicine
Obstructive Sleep Apnea Breakthroughs: Emerging and Newly Approved Treatment Updates - Frankly Speaking Ep 425

Frankly Speaking About Family Medicine

Play Episode Listen Later Mar 24, 2025 12:38


Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-425 Overview: In this episode we discuss updates on the treatment and management of obstructive sleep apnea (OSA). This is a common health concern, but it is often underdiagnosed and can have significant health impacts. We review its prevalence and standard treatments, highlighting the recently used medication therapy that has been found to be effective in treating OSA, particularly in individuals with obesity.  Episode resource links: https://www.aafp.org/pubs/afp/issues/2023/0300/uspstf-obstructive-sleep-apnea.html https://emedicine.medscape.com/article/295807-overview Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., ... & Bednarik, J. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. Mangione, C. M., Barry, M. J., Nicholson, W. K., Cabana, M., Chelmow, D., Coker, T. R., ... & US Preventive Services Task Force. (2022). Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement. Jama, 328(19), 1945-1950. https://aasm.org/rising-prevalence-of-sleep-apnea-in-u-s-threatens-public-health/ Guest: Mariyan L. Montaque, DNP, FNP-BC  Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Pri-Med Podcasts
Obstructive Sleep Apnea Breakthroughs: Emerging and Newly Approved Treatment Updates - Frankly Speaking Ep 425

Pri-Med Podcasts

Play Episode Listen Later Mar 24, 2025 12:38


Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-425 Overview: In this episode we discuss updates on the treatment and management of obstructive sleep apnea (OSA). This is a common health concern, but it is often underdiagnosed and can have significant health impacts. We review its prevalence and standard treatments, highlighting the recently used medication therapy that has been found to be effective in treating OSA, particularly in individuals with obesity.  Episode resource links: https://www.aafp.org/pubs/afp/issues/2023/0300/uspstf-obstructive-sleep-apnea.html https://emedicine.medscape.com/article/295807-overview Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., ... & Bednarik, J. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. Mangione, C. M., Barry, M. J., Nicholson, W. K., Cabana, M., Chelmow, D., Coker, T. R., ... & US Preventive Services Task Force. (2022). Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement. Jama, 328(19), 1945-1950. https://aasm.org/rising-prevalence-of-sleep-apnea-in-u-s-threatens-public-health/ Guest: Mariyan L. Montaque, DNP, FNP-BC  Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Talking Sleep
Tirzepatide & OSA: Implementation for Sleep Clinics

Talking Sleep

Play Episode Listen Later Mar 21, 2025 47:27


In this episode, host Dr. Seema Khosla explores a transformative development in sleep medicine: the FDA approval of tirzepatide for obstructive sleep apnea (OSA). Joined by an expert panel including Dr. Atul Malhotra, lead investigator of the SURMOUNT-OSA trial, and specialists Dr. Radhika Breaden, Dr. Jeremy McConnell, and Dr. Rafael Sepulveda-Acosta, the discussion examines how sleep clinicians can effectively incorporate this groundbreaking medication into their treatment protocols.  Discover key insights about the SURMOUNT-OSA trial results published in the New England Journal of Medicine, including the mechanisms behind AHI improvement beyond weight reduction alone. Learn practical implementation strategies for private practices, including documentation requirements for insurance approval, necessary baseline labs, and optimal patient follow-up protocols. The experts address crucial questions about Medicare coverage, long-term medication management, the need for retesting at goal weight, and considerations for transitioning patients already using GLP-1 medications like Ozempic or Wegovy.  This episode provides essential guidance for sleep medicine specialists considering expanding their treatment options beyond traditional PAP therapy, including collaborations with obesity medicine clinics and whether obtaining board certification in Obesity Medicine would benefit sleep clinicians. This timely discussion equips practitioners with the knowledge to navigate the intersection of sleep medicine and obesity treatment in managing OSA patients 

The Gary Null Show
The Gary Null Show 3.11.25

The Gary Null Show

Play Episode Listen Later Mar 11, 2025 57:51


Dr. Gary Null gives a commentary on his article "It's Time for a Vaccination Reckoning"   Ask any federal health official—whether from the FDA, CDC, NIH, or National Cancer Institute—if vaccines contribute to neurological damage or autism, and their response will be unequivocal: No, there is no evidence of any association. In fact, they might find the very question offensive. After all, these agencies have access to unlimited resources, the brightest scientific minds, and cutting-edge research facilities at institutions like Harvard, Johns Hopkins, and Stanford. If there were any credible link between vaccines and neurological harm, surely, they would have found it by now. And yet, despite decades of investigation and countless opportunities, their stance remains unchanged: vaccines are safe and effective. Any claim to the contrary is dismissed as conspiracy theory and an assault on the very foundations of modern medicine. This has been the dominant narrative for the past forty years. Federal health officials and policymakers have long prioritized private pharmaceutical industry interests and upheld the belief that vaccination is the single most important tool for eradicating infectious diseases. Dissent is neither tolerated nor entertained. The agencies responsible for vaccine safety, such as HHS, FDA, NIAID and the CDC, are ruled by a rigid scientific orthodoxy that allows no room for alternative perspectives. But now, for the first time in modern history, an outsider has entered the room. Robert F. Kennedy Jr., the new head of the Department of Health and Human Services, is neither a scientist nor a physician. Unlike his predecessors, he has no allegiance to the status quo. His appointment signals a possible turning point to usher a new opportunity for a truly independent investigation into whether vaccines, either individually or collectively, contribute to neurological damage. If pursued earnestly, this could be one of the most consequential moments in American medical history. The stakes could not be higher. Over the past few decades, childhood chronic illnesses have skyrocketed to unprecedented levels. The rise in autism spectrum disorders (ASD), ADHD, autoimmune conditions, and other neurological and developmental disorders has been explained away as the result of better diagnostic tools or genetic predispositions. But are these explanations sufficient? What if something more fundamental has changed in children's health over the past 30 years? Federal health agencies continue to dismiss environmental factors, including vaccines, as a potential cause. But if we truly care about children's well-being, it is time to ask the hard questions. And we must ask without fear, without bias, and without ideological blinders. The dramatic increase in neurological disorders, including autism spectrum disorders that is now diagnosed in 1 in every 36 children, has often been attributed to improved definitions for ASD and diagnostic tools. However, a closer look at government statistics reveals alarming trends in children's health that go far beyond better diagnostics. Since the early 1990s, there has been a staggering increase in several chronic conditions: ADHD rates have risen by 890 percent, autism diagnoses by 2,094 percent, bipolar disease in youth by 10,833 percent, and celiac disease by 1,011 percent. These numbers beg the question—what has fundamentally changed in our children's health over the past three decades? The media plays a crucial role in reinforcing the official vaccine narrative while systematically silencing dissenting voices. This lack of transparency allows federal health agencies like the CDC, NIAID, and HHS to evade accountability. Instead of safeguarding public health, these institutions have become politically and ideologically entangled with private pharmaceutical interests. Their close ties to the industry have led to the approval of insufficiently tested vaccines, the medicalization of normal childhood behaviors, and the delivery of subpar healthcare—all at a staggering cost of $5 trillion annually. Medical authorities insist that vaccines, even when administered in multiple doses on a single day, are safe and do not cause chronic health problems. They claim that vaccine ingredients are either harmless or present in amounts too small to pose any risk. Any attempt to challenge these assertions is met with ridicule. Despite a sharp rise in childhood neurological disorders, there has been no significant push for reform or independent long-term safety studies on the effects of vaccines. For decades, concerns about vaccine safety have not only come from parents and advocacy groups but also from government investigations. A three-year congressional investigation led by Rep. Dan Burton strongly criticized the CDC, FDA, and HHS for their failure to conduct proper vaccine safety studies. The committee found that federal agencies systematically downplayed risks, ignored growing evidence of vaccine-related neurological disorders, and relied on poorly designed epidemiological studies rather than clinical research. The report also exposed the failure of vaccine manufacturers to conduct adequate safety testing, highlighting decades of negligence. Despite these damning conclusions, little has changed, and concerns about vaccine safety remain unaddressed. While thimerosal has been largely removed from childhood vaccines, it remains in some flu shots and multi-dose vials, and broader concerns about vaccine ingredients and neurological damage continue to grow. One of the most alarming revelations came from the secretive 2000 Simpsonwood meeting, where top CDC officials and vaccine industry representatives discussed an internal study linking thimerosal exposure to increased risks of tics, ADHD, speech delays, and developmental disorders. Instead of alerting the public, the attendees decided to suppress the findings and rework the data to obscure any association. This manipulation, later exposed by Robert Kennedy Jr. through a Freedom of Information Act request, exemplifies the CDC's ongoing pattern of data suppression and scientific misconduct when vaccine safety is called into question. The congressional committee later confirmed that many participants in the vaccine debate “allowed their standards to be dictated by their desire to disprove an unpleasant theory.” Rather than conducting thorough biological studies to assess vaccine safety, federal agencies have deflected scrutiny by blaming autism and other neurological conditions on genetic factors, despite a lack of conclusive evidence supporting this theory. Today's CDC childhood immunization schedule recommends over 27 vaccines by the age of two, with some visits involving up to six shots at once. Parents are expected to trust that these vaccines are rigorously tested and proven safe. However, a review of hundreds of toxicology and immunology studies fails to reveal a gold standard of long-term, double-blind, placebo-controlled trials proving vaccine safety. There is also no comprehensive epidemiological study comparing the long-term health outcomes of fully vaccinated versus unvaccinated children. Without this research, public health officials rely on inconclusive data, which is shaped more by policy than by science. Humans possess unique biochemical makeups that make them more or less susceptible to toxins. While one child may experience minor effects from environmental toxins, another may develop autoimmune disorders, learning disabilities, or neurological impairments. Vaccine safety cannot be proven simply by stating that not every vaccinated child has autism. Given the dramatic rise in autoimmune diseases, food allergies, encephalitis, and conditions like Crohn's disease, it is imperative to investigate environmental toxins' role in childhood health. Independent research suggests that ingredients in vaccines, even in small amounts, may contribute to these illnesses, particularly as the number of required vaccines continues to grow. Ironically, the U.S. government's own Vaccine Injury Compensation Program (VICP) has awarded settlements to families whose children developed autism-like symptoms following vaccination. High-profile cases such as Hannah Poling, who developed ASD after receiving nine vaccines in one day, Ryan Mojabi, whose vaccines caused severe brain inflammation, and Bailey Banks, who suffered vaccine-induced brain inflammation leading to developmental delays, demonstrate that vaccine injury can, in some cases, result in autism spectrum disorders. A broader analysis of VICP cases revealed that 83 children with autism were compensated for vaccine-related brain injuries, primarily involving encephalopathy or seizure disorders with developmental regression. These cases contradict federal health agencies' claims that no connection between vaccines and autism has ever been recognized. The National Library of Medicine lists over 3,000 studies on aluminum's toxicity to human biochemistry. Its dangers have been known for over a century. Early FDA director Dr. Harvey Wiley resigned in protest over aluminum's commercial use in food canning as early as 1912. Today, aluminum compounds, such as aluminum hydroxide and aluminum phosphate, are found in many vaccines, including hepatitis A and B, DTP, Hib, Pneumococcus, and the HPV vaccine (Gardasil). In the 1980s, a fully vaccinated child would have received 1,250 mcg of aluminum by adulthood. Today, that number has risen to over 4,900 mcg, a nearly fourfold increase. Aluminum exposure is further compounded by its presence in municipal drinking water due to aluminum sulfate used in purification. A 1997 study published in the New England Journal of Medicine found that premature infants receiving aluminum-containing intravenous feeding solutions developed learning problems at a significantly higher rate than those who received aluminum-free solutions. Dr. James Lyons-Weiler at the Institute for Pure and Applied Knowledge has criticized vaccine aluminum levels, pointing out that dosage guidelines are based on immune response rather than body weight safety. Alarmingly, aluminum exposure standards for children are based on dietary intake studies in rodents rather than human infants. He notes that on Day 1 of life, newborns receive 17 times more aluminum than would be permitted if doses were adjusted per body weight. Despite these findings, federal agencies continue to dismiss concerns over aluminum toxicity in vaccines. The refusal to conduct comprehensive long-term safety studies, coupled with regulatory agencies' deep entanglement with the pharmaceutical industry, has led to a public health crisis. The growing prevalence of neurological and autoimmune disorders in children demands urgent, unbiased investigation into environmental and vaccine-related factors. Until federal health agencies commit to transparency and rigorous scientific inquiry, parents will be left to navigate vaccine safety decisions without the full picture of potential risks. Christopher Exley at Keele University analyzed brain tissue from children and teenagers diagnosed with ASD and found consistently high aluminum levels, among the highest recorded in human brain tissue. The aluminum was concentrated in inflammatory non-neuronal cells across various brain regions, supporting its role in ASD neuropathology. In a systematic review of 59 studies, Exley found significant associations between aluminum, cadmium, mercury, and ASD, further underscoring aluminum's neurotoxic impact. His research strongly advocates for reducing vaccine-derived aluminum exposure in pregnant women and children to help mitigate the rise in autism. Despite the CDC's consistent denials, researchers at Imperial College London found a significant correlation between rising ASD rates and increased vaccination. Their 2017 study in Metabolic Brain Disease showed that a 1% increase in vaccination rates correlated with 680 additional ASD cases, raising urgent concerns over vaccine components as environmental triggers. CDC whistleblower Dr. William Thompson provided thousands of pages of internal research revealing a cover-up of vaccine-autism links. His documents proved the CDC had prior knowledge that African American boys under 36 months had a significantly higher autism risk following the MMR vaccine and that neurological tics—indicators of brain disturbances—were linked to thimerosal-containing vaccines like the flu shot. Yet, instead of acknowledging this risk, federal agencies buried, in fact shredded, the findings, ensuring that vaccine safety concerns were dismissed as conspiracy theories rather than investigated as public health imperatives. The official denial of a vaccine-autism connection has become entrenched dogma, unsupported by a single gold-standard study definitively disproving such a link. Meanwhile, the health of American children continues to decline, ranking among the worst in the developed world. Neurodevelopmental disorders like autism and ADHD are at crisis levels, yet federal agencies remain unwilling to conduct the comprehensive safety studies that could expose the full impact of mass vaccination on childhood health. Now, with Robert F. Kennedy Jr. at the helm of the Department of Health and Human Services, a long-overdue reckoning may finally be at hand. Unlike his predecessors, Kennedy is an advocate for transparency and accountability. If pursued earnestly, Kennedy's leadership could potentially reshape public health policies and exposing the truth about vaccines' role in the rise of neurological disorders, including autism. The question now is: Will the truth finally be allowed to come to light?

Diet Science
Stop the Microplastics Mayhem! Proactive Steps to Minimize Exposure

Diet Science

Play Episode Listen Later Mar 9, 2025 14:57


Microplastics are tiny plastic particles—smaller than a grain of sand—shed from bottles, bags, tires, synthetic fabrics, and even cosmetics. Linked to obesity, diabetes, heart disease, Alzheimer's, and cancer, these invisible invaders are everywhere. Listen in this week as Dee shares nutrition and detox strategies to help clear them from your body.Reference:Marfella, R., Prattichizzo, F., Sardu, C., Fulgenzi, G., Graciotti, L., Spadoni, T., D'Onofrio, N., Scisciola, L., La Grotta, R., Frigé, C., Pellegrini, V., Municinò, M., Siniscalchi, M., Spinetti, F., Vigliotti, G., Vecchione, C., Carrizzo, A., Accarino, G., Squillante, A., . . . Paolisso, G. (2024). Microplastics and nanoplastics in atheromas and cardiovascular events. New England Journal of Medicine, 390(10), 900–910. https://www.nejm.org/doi/10.1056/NEJMoa2309822

Sky Women
Episode 197: Male partner treatment to prevent recurrent BV

Sky Women

Play Episode Listen Later Mar 9, 2025 11:46


In this episode, Dr. Carolyn Moyers dives into groundbreaking research published in The New England Journal of Medicine (March 6, 2025), shedding new light on bacterial vaginosis (BV) management. A randomized controlled trial from Australia, involving 164 couples, found that treating male partners significantly reduced BV recurrence rates by half over 12 weeks.This study challenges conventional treatment approaches and suggests BV may function more like a sexually transmitted infection (STI) than previously thought. Dr. Moyers discusses the implications for clinical practice, the ongoing challenges in managing persistent and recurrent BV, and the broader health risks associated with bacterial vaginosis.

Healthcare Unfiltered
Smoldering Myeloma: The Epic Debate

Healthcare Unfiltered

Play Episode Listen Later Feb 25, 2025 70:04


Returning to the show, Drs. Vincent Rajkumar and Aaron Goodman engage in a dynamic debate over the evolving landscape of smoldering multiple myeloma, focusing on the highly anticipated study recently co-authored by Dr. Rajkumar and published in The New England Journal of Medicine after being presented at ASH 2024. They dissect the study's findings, which highlight the impact of early intervention with daratumumab in delaying disease progression for patients classified as high-risk. The discussion explores the nuances of smoldering myeloma classification, the controversy surrounding risk stratification, and the historical context of prior studies that failed to change clinical practice. With their expert insights, Drs. Rajkumar and Goodman break down the implications of this research, questioning whether it truly shifts the standard of care and what it means for future treatment approaches. View the NEJM publication. https://www.nejm.org/doi/abs/10.1056/NEJMoa2409029 Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

The Doctor's Farmacy with Mark Hyman, M.D.
Can Food Really Heal Your Brain? | Dr. Jeff Bland & Dr. William Li

The Doctor's Farmacy with Mark Hyman, M.D.

Play Episode Listen Later Feb 24, 2025 55:39


There is a significant impact of food on brain health and overall well-being, with great importance placed on nutrient-dense, anti-inflammatory foods. Unfortunately, nutrient levels of modern crops are declining, but regenerative agriculture is helping to restore food quality. Specific brain-boosting foods such as leafy greens, small cold-water fish, and polyphenol-rich plants have an ability to reduce neuroinflammation, protect against cognitive decline, and enhance mental clarity. And, ultimately, identifying whole food sources of essential nutrients will support your entire body. In this episode, I discuss, along with Dr. Jeff Bland and Dr. William Li, practical tips on choosing the most nutrient-dense foods and how to harness their benefits for overall health. Dr. Jeff Bland is the founder of Big Bold Health, a company on a mission to transform the way people think about one of nature's greatest innovations—the immune system. Through Big Bold Health, Dr. Bland is advocating for the power of Immuno-Rejuvenation to enhance immunity at a global level, often through the rediscovery of ancient food crops and superfoods. To get there, he is building a network of small farms and suppliers throughout the US that take a clear stance on regenerative agriculture, environmental stewardship, and planetary health. Dr. Bland's career in health spans more than 40 years. A nutritional biochemist by training, he began in academia as a university professor. He then spent three decades in the natural products industry, working alongside other pioneers. A lifelong educator, Dr. Bland has traveled the world many times over in his role as the “father of functional medicine.” In 1991, he and his wife, Susan, founded The Institute for Functional Medicine. In 2012, he founded another educational nonprofit called the Personalized Lifestyle Medicine Institute. Dr. Bland is the author of The Disease Delusion: Conquering the Causes of Chronic Illness for a Healthier, Longer, and Happier Life, as well as countless additional books and research papers. Dr. William Li is a world-renowned physician, scientist, speaker, and author of Eat to Beat Disease: The New Science of How Your Body Can Heal Itself. He is best known for leading the Angiogenesis Foundation. His groundbreaking work has impacted more than 70 diseases including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, Can We Eat to Starve Cancer? has garnered more than 11 million views, and he has appeared on The Dr. Oz Show, Martha Stewart Live, CNN, MSNBC, NPR, Voice of America, and has presented at the Vatican's Unite to Cure conference. An author of over 100 scientific publications in leading journals such as Science, The New England Journal of Medicine, The Lancet, and more, Dr. Li has served on the faculties of Harvard, Tufts, and Dartmouth Medical School. Find Dr. Li's Eat To Beat Disease Masterclass at drwilliamli.com/masterclass and get a copy of his book, Eat To Beat Disease at drwilliamli.com/book-li/. Full length episodes can be found here: Nourish Your Brain with These Powerful Superfoods https://drhyman.com/blogs/content/podcast-ep909?_pos=1&_sid=652901034&_ss=r How The Most Important Superfood You've Never Heard About Will Rejuvenate Your Immune System https://drhyman.com/blogs/content/podcast-ep176?_pos=10&_sid=652901034&_ss=r Cancer Can't Stand This Diet: Dr. William Li's Anti-Cancer Nutrition Breakthroughs https://drhyman.com/blogs/content/podcast-ep890?_pos=4&_sid=ec054bdd0&_ss=r This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%.

Cardionerds
411. Journal Club: The VANISH2 Trial with Dr. Jeff Healey and Dr. Roderick Tung

Cardionerds

Play Episode Listen Later Feb 24, 2025 30:05


Join CardioNerds EP Council Chair Dr. Naima Maqsood and Episode Lead Dr. Jeanne De Lavallaz as they discuss the results of the VANISH2 Trial with expert faculty Dr. Jeff Healey and Dr. Roderick Tung. Audio editing by CardioNerds academy intern, Grace Qiu. The VANISH2 trial enrolled 416 patients with ischemic cardiomyopathy, an ICD in place, and recurrent episodes of sustained monomorphic ventricular tachycardia (VT) to receive either first-line VT catheter ablation or antiarrhythmic drug therapy with the primary composite outcome of death from any cause, appropriate ICD shock, ventricular tachycardia storm (meaning at least 3 ventricular tachycardia events within 24hrs) or treated ventricular tachycardia below the detection limit of the ICD. The study population had a mean age of 68 years, with 94% being men and predominantly of white ethnicity. On average, 14 years had elapsed since their last myocardial infarction, with approximately 60% having undergone percutaneous coronary intervention at the time. The mean ejection fraction was 34%. This episode was planned in collaboration with Heart Rhythm TV with mentorship from Dr. Daniel Alyesh and Dr. Mehak Dhande. CardioNerds Journal Club PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References - VANISH2 Trial Sapp, J. L., Tang, A. S. L., Parkash, R., Stevenson, W. G., Healey, J. S., Gula, L. J., Nair, G. M., & the VANISH2 Study Team. (2025). Catheter ablation or antiarrhythmic drugs for ventricular tachycardia. The New England Journal of Medicine, 392, 737–747.

Kevin Kietzman Has Issues
Mizzou is Saving CBB, Chiefs Prez Eyes KS, Team USA Ready, Trump Wants DC Takeover, Sec Promises Low Rates, Tony's KC Sums Up Lester Saga, CA Town Trolls Libs

Kevin Kietzman Has Issues

Play Episode Listen Later Feb 20, 2025 49:39


   It may not make the New England Journal of Medicine but we have found a cure for the college basketball doldrums... the Missouri Tigers.  Let's call them the Fast and Furious as they are must watch material popping #4 Alabama scoring 110 points.  Mizzou and Auburn are the most fun teams in America to watch.  I don't care how it happened I'm just glad it did.    According to my sources, Chiefs President Mark Donovan is all in on a shiny new stadium at the Legends in KCK where KC can host a Super Bowl.  His one last hurdle is to convince owner Clark Hunt its the best thing to do.  We'll share the one hurdle Donovan has to clear to get it done.    Team USA Hockey is ready to rock Thursday night against Canada... this time on American ice in Boston.  I've got one request from the fans.    Trump says he wants to take over Washington DC and federalize it.  Trump says it's embarrassing for visiting world leaders to see what its become.    The new commerce secretary is a shot of adrenaline and is fired up for how quickly he believes Trump's policies will turn around the economy and bring down interest rates.    Tony Botello of www.tonyskansascity.com pens a thoughtful piece about the final years of Andrew Lester's life.  Lester was the scared old man that shot the kid on his porch a couple years ago, pleaded guilty to assault just days ago and then died on Wednesday.  So sad.    A former NFL kicker misses wide left in front of a fully right city council in our new favorite community in LA and what is "fowling?"   I wanna play.

Something You Should Know
Lessons on Health from the Animal Kingdom & How to Manage Your Emotions

Something You Should Know

Play Episode Listen Later Feb 6, 2025 52:48


How many times have you wanted to ask for a raise but didn't bother because you knew the answer would be no? Well, you probably should've asked anyway. This episode begins with some surprising statistics about the power of asking for a raise. https://www.huffpost.com/entry/getting-a-raise_n_6429324 The animal kingdom can teach us a lot about improving human health. For example, elephants almost never get cancer – yet humans do. Why is that? Pigs can teach us how to control pain. Dogs can teach us to manage stress and there are a lot more examples as you are about to hear from my guest Dr. David Agus. He is a medical oncologist, and one of the world's pioneering biomedical researchers. David is the Founding CEO of the Ellison Medical Institute and a professor of medicine and engineering at the University of Southern California.He is also the author of The Book of Animal Secrets: Nature's Lessons for a Long and Happy Life (https://amzn.to/4ghXL5b) We've all had moments when our emotions got the best of us. Whether we get so angry, or anxious or sad that it gets in the way of daily living, damages relationships or gets us into serious trouble. While some people seem good at keeping their emotions under control, many of us could use some help. And here to share his insight into this is Ethan Kross, one of the world's leading experts on emotion regulation. Ethan is an award-winning professor at the University of Michigan and his work has been featured in The New York Times, The Wall Street Journal, The New Yorker, and The New England Journal of Medicine. He is the author of a book called Shift: Managing Your Emotions So They Don't Manage You (https://amzn.to/3CAxQYU). “Tech neck” is a real condition that results from always looking down at your phone. Listen as I explain how that little tilt in your neck can mess up your posture and cause real problems. https://www.mayoclinichealthsystem.org/hometown-health/speaking-of-health/effect-of-technology-on-your-neck PLEASE SUPPORT OUR SPONSORS!!! FACTOR: Eat smart with Factor! Get 50% off at https://FactorMeals.com/something50off DELL: Anniversary savings await you for a limited time only at https://Dell.com/deals SHOPIFY:  Nobody does selling better than Shopify! Sign up for a $1 per-month trial period at https://Shopify.com/sysk and upgrade your selling today! HERS: Hers is changing women's healthcare by providing access to GLP-1 weekly injections with the same active ingredient as Ozempic and Wegovy, as well as oral medication kits. Start your free online visit today at https://forhers.com/sysk INDEED: Get a $75 sponsored job credit to get your jobs more visibility at https://Indeed.com/SOMETHING right now! CURIOSITY WEEKLY: We love Curiosity Weekly, so listen wherever you get your podcasts! Learn more about your ad choices. Visit megaphone.fm/adchoices

Freakonomics Radio
617. Are You Really Allergic to Penicillin?

Freakonomics Radio

Play Episode Listen Later Jan 10, 2025 63:50


Like tens of millions of people, Stephen Dubner thought he had a penicillin allergy. Like the vast majority, he didn't. This misdiagnosis costs billions of dollars and causes serious health problems, so why hasn't it been fixed? And how about all the other things we think we're allergic to? SOURCES:Kimberly Blumenthal, allergist-immunologist and researcher at Mass General Hospital and Harvard Medical School.Theresa MacPhail, associate professor of science and technology studies at Stevens Institute of Technology.Thomas Platts-Mills, professor of medicine at the University of Virginia.Elena Resnick, allergist and immunologist at Mount Sinai Hospital. RESOURCES:Allergic: Our Irritated Bodies in a Changing World, by Theresa MacPhail (2023)."Evaluation and Management of Penicillin Allergy: A Review," by Erica S. Shenoy, Eric Macy, and Theresa Rowe (JAMA, 2019)."The Allergy Epidemics: 1870–2010," by Thomas Platts-Mills (The Journal of Allergy and Clinical Immunology, 2016)."Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy," by George Du Toit, Graham Roberts, et al. (The New England Journal of Medicine, 2015). EXTRAS:Freakonomics, M.D.